West China Hospital of Sichuan University

The Rehabilitation Medicine Center of West China Hospital, Sichuan University, is a national key clinical specialty. It serves as the chairman unit of the Physical Medicine and Rehabilitation Branch of the Chinese Medical Association and a vice-chairman unit of the Chinese Association of Rehabilitation Medicine. Its rehabilitation medicine program has consistently ranked first in the nation for many years in Fudan University's ranking of specialized disciplines (ranking first in both specialized reputation and overall ranking in 2022 and 2023). With neurorehabilitation as one of its core advantageous sub-disciplines, it was the first unit in mainland China to offer full-time undergraduate programs in rehabilitation medicine. Its three specialties—physical therapy, occupational therapy, and prosthodontics—have all received international accreditation (WCPT/WFOT/ISPO). The center is positioned as a core source for aligning China's modern rehabilitation medicine education system with international standards and a leader in the rehabilitation of complex and critical illnesses nationwide.

Historical Origins and Spiritual Inheritance:

The history of West China Rehabilitation can be traced back to 1929, when Cunren Hospital began using physical factors to treat diseases. In 1933, American Paul Weir opened a clinical physiotherapy course at West China Union University. In December 1951, West China Union University Hospital established the Department of Physical Therapy and the Department of Occupational Therapy, marking the formal establishment of West China Rehabilitation. In September 1989, the Rehabilitation Medicine Center was officially established. Through the inheritance and development of several generations of academic leaders such as Xiong Enfu and He Chengqi, the center has developed from the initial Department of Physical Therapy into a modern rehabilitation medicine center integrating medical treatment, teaching, research, and production. Professor He Chengqi, as the discipline director, leads a national key clinical specialty, which ranks first in the country at Fudan University. The rehabilitation therapy major at Sichuan University, which he also leads, is ranked A+ in the Soft Science China University Major Ranking and was selected as one of the first batch of national first-class majors.

Core business operational efficiency:

The center has 211 beds and 283 staff members, including 46 senior professionals, 117 master's degree holders, 51 doctoral degree holders, and 35 postdoctoral fellows. The center comprises four wards, twenty-three subspecialties, twelve treatment departments, five research laboratories, and seven specialized centers, forming a distinctive specialty based on specific diseases, oriented towards functional rehabilitation, and centered on rehabilitation technology. The neurorehabilitation section, as one of the center's core subspecialties, covers functional rehabilitation for cerebrovascular diseases, brain injuries, neurocritical care rehabilitation, spinal cord injuries, peripheral nerve injuries, Parkinson's disease, and Alzheimer's disease. The center specializes in the rehabilitation of complex and critical illnesses and provides a systematic specialized learning platform for trainees from all over the country each year.

Discipline Positioning and Benchmarking:

It is a national key clinical specialty, the chairman unit of the Physical Medicine and Rehabilitation Branch of the Chinese Medical Association, the vice-president unit of the Chinese Association of Rehabilitation Medicine, and the director unit of the Sichuan Provincial Key Laboratory of Rehabilitation Medicine. The center possesses several "firsts in mainland China," including the first joint doctoral program in physical therapy, occupational therapy, and prosthodontics. Its rehabilitation medicine program has consistently ranked first in the nation for many years in Fudan University's ranking of specialty reputation, and in 2022, it ranked first in both specialty reputation and overall ranking.

The Rehabilitation Medicine Center of West China Hospital, Sichuan University, is a national key clinical specialty and the chairman unit of the Physical Medicine and Rehabilitation Branch of the Chinese Medical Association, as well as the vice-president unit of the Chinese Association of Rehabilitation Medicine. The center's rehabilitation medicine program has consistently ranked first in the national reputation rankings by Fudan University for many years (ranking first in both specialty reputation and overall rankings for two consecutive years in 2022 and 2023). Orthopedics/Joint Rehabilitation, as the center's oldest and most traditionally advantageous subspecialty, holds a leading position nationwide in the rehabilitation assessment and treatment of post-fracture surgery, post-joint replacement surgery, osteoporosis, osteoarthritis, and sports injuries. It is one of the core clinical directions of the first full-time undergraduate rehabilitation program in mainland China.

Historical Origins and Spiritual Inheritance:

The history of West China Rehabilitation can be traced back to physical factor therapy initiated at Cunren Hospital in 1929. In December 1951, West China Union University Hospital established the Department of Physical Therapy and the Department of Occupational Therapy, marking the formal establishment of West China Rehabilitation. Orthopedic rehabilitation has been listed as one of the core directions since the subspecialty grouping in 2006, with Professor He Chengqi serving as the head of the Orthopedic Rehabilitation Group, and members including Chen Peng and Lei Zhongjie. After decades of development, the orthopedic/joint rehabilitation direction has formed a complete rehabilitation system from early post-fracture intervention to functional reconstruction after joint replacement surgery.

Core business operational efficiency:

The Rehabilitation Medicine Center has 211 beds and 283 staff members, including 46 senior professionals, 51 PhDs, and 35 postdoctoral fellows. The center comprises four wards, twenty-three subspecialties, twelve treatment departments, five research laboratories, and seven specialized centers. The Orthopedics/Joint Rehabilitation specialization is jointly undertaken by the Musculoskeletal Rehabilitation Ward (directed by Professor Lei Zhongjie) and the Orthopedic Rehabilitation Clinic (officially staffed by Professors He Chengqi and Liang Qiu), covering subspecialties such as post-fracture surgery rehabilitation, post-joint replacement surgery rehabilitation, osteoporosis rehabilitation, osteoarthritis rehabilitation, sports injury rehabilitation, and hand injury and burn rehabilitation.

Discipline Positioning and Benchmarking:

It is a national key clinical specialty, the chairman unit of the Physical Medicine and Rehabilitation Branch of the Chinese Medical Association, and the vice-president unit of the Chinese Association of Rehabilitation Medicine. Professor He Chengqi serves as the 8th chairman of the Physical Medicine and Rehabilitation Branch of the Chinese Medical Association and the vice-president of the Chinese Association of Rehabilitation Medicine. His leading discipline is a national key clinical specialty, ranked first in the country by Fudan University. The center's three specialties—physical therapy, occupational therapy, and prosthodontics—have all passed international accreditations (WCPT/WFOT/ISPO).

The Rehabilitation Medicine Center of West China Hospital, Sichuan University, is a national key clinical specialty and a vice-chairman unit of the Physical Medicine and Rehabilitation Branch of the Chinese Medical Association, as well as a vice-president unit of the Chinese Association of Rehabilitation Medicine. For many consecutive years, the center's rehabilitation medicine program has ranked first in the national reputation rankings of Fudan University's specialized programs. Spinal cord injury rehabilitation, as one of the core directions among the center's 23 sub-specialties, is specifically undertaken by the Spinal Cord Injury Rehabilitation Comprehensive Ward (led by Associate Professors Ding Mingfu and Wang Qian). It holds a leading position nationally in the fields of full-cycle rehabilitation of limb paralysis and paraplegia, neurogenic bladder and bowel management, cardiopulmonary rehabilitation, and clinical translation of brain-computer interfaces. It is one of the core clinical directions of the first full-time undergraduate rehabilitation program in mainland China.

Historical Origins and Spiritual Inheritance:

The history of West China Rehabilitation can be traced back to physical factor therapy initiated at Cunren Hospital in 1929. In December 1951, West China Union University Hospital established the Department of Physical Therapy and the Department of Occupational Therapy, marking the formal establishment of West China Rehabilitation. In September 1989, the Rehabilitation Medicine Center was officially established. In 2013, the center was designated a National Key Clinical Specialty (one of only ten nationwide). Spinal cord injury rehabilitation has been a core focus since the center's subspecialty system was established, and after decades of development, it has formed a complete system from acute bedside rehabilitation to functional reconstruction in the recovery phase.

Core business operational efficiency:

The center has 211 beds and 226 staff members, including 29 senior professionals, 80 master's degree holders, 37 doctoral degree holders, and 23 postdoctoral fellows. The center comprises four wards (including a spinal cord injury rehabilitation ward), twenty-three subspecialties, twelve treatment departments, five research laboratories, and six diagnostic and treatment centers. The spinal cord injury rehabilitation ward operates as an independent ward, with Associate Professor Ding Mingfu serving as the ward director, Associate Professor Wang Qian as the deputy director, and Associate Chief Nurse Zhang Jianmei as the head nurse. Professor Wei Quan has presided over one National Key Research and Development Program project (Chief Scientist) and three National Natural Science Foundation of China projects. He has published 81 SCI papers as the first/corresponding author, with the highest single-paper impact factor (IF) of 52.7 and a total impact factor of over 450. He has won the first prize (2nd author) and the second prize (1st author) of the Science and Technology Award of the Chinese Association of Rehabilitation Medicine.

Discipline Positioning and Benchmarking:

It is a national key clinical specialty, a vice-chairman unit of the Physical Medicine and Rehabilitation Branch of the Chinese Medical Association (Professor Wei Quan was elected in 2025), and a vice-president unit of the Chinese Association of Rehabilitation Medicine. The center has a key laboratory for rehabilitation medicine in Sichuan Province, and its three specialties—physical therapy, occupational therapy, and prosthodontics—have all passed international accreditation (WCPT/WFOT/ISPO). In 2023, the 11th West China International Rehabilitation Forum will establish a sub-forum on precision rehabilitation for spinal cord injury, co-chaired by Professor Andrei Krassioukov, former president of the American Spinal Cord Injury Association (ASIA), Professor Wei Quan, and Professor Ding Mingfu.

The Cardiopulmonary and Critical Care Rehabilitation Team of the Rehabilitation Medicine Center at West China Hospital of Sichuan University is one of the core subspecialties of the National Key Clinical Specialty of West China Rehabilitation Medicine Center. The discipline is characterized by its flagship strength in cardiopulmonary and critical care physical therapy, and its distinctive technical system is interdisciplinary precision cardiopulmonary critical care physical therapy. In the 2025 Third National Clinical Case Competition of Physical Therapy of the Chinese Association of Rehabilitation Medicine, the team stood out from 142 participating teams nationwide, winning the only first prize. Professor Wei Quan serves as the Vice Chairman of the Physical Medicine and Rehabilitation Branch of the Chinese Medical Association, and Professor Yu Pengming serves as the Chairman of the Advanced Physical Therapist Certification Course of the Asia Pacific Cardiopulmonary Rehabilitation Association. They are positioned as clinical demonstrators and physical therapy education leaders in the field of cardiopulmonary and critical care rehabilitation nationwide.

Historical Origins and Spiritual Inheritance:

The West China Rehabilitation Medicine Center boasts a long history, dating back to the physical factor therapy that began at Cunren Hospital in 1929. In December 1951, West China Union University Hospital established a Department of Physical Therapy and a Department of Occupational Therapy, marking the formal establishment of West China Rehabilitation. The Rehabilitation Medicine Center was officially established in September 1989. Cardiopulmonary and critical care rehabilitation, as one of the center's core subspecialties, has gradually developed into a precision cardiopulmonary critical care physical therapy system under the leadership of Professors Wei Quan and Yu Pengming, based on the concept of "integrated clinical and rehabilitation care" and a multidisciplinary collaborative framework.

Core business operational efficiency:

The Rehabilitation Medicine Center boasts a Sichuan Provincial Key Laboratory of Rehabilitation Medicine and a Clinical Research Laboratory of Physical Medicine and Rehabilitation, forming six comprehensive research directions, including basic and clinical cardiopulmonary rehabilitation. The center has twelve treatment departments, including a cardiopulmonary rehabilitation physical therapy department. The cardiopulmonary and critical care rehabilitation team is dedicated to providing patients with high-quality rehabilitation medical services, helping them achieve functional recovery and maximize their quality of life through precise assessment, personalized treatment, and humanistic care. Professor Wei Quan has presided over one National Key Research and Development Program project (Chief Scientist), one National Key Research and Development Program medley, and three National Natural Science Foundation of China projects. He has published 81 SCI papers as the first/corresponding author, with the highest single-paper impact factor (IF) at 52.7 and a total impact factor (IF) of over 450. He has received awards such as the Second Prize of the Science and Technology Award from the Chinese Association of Rehabilitation Medicine (First Author).

Discipline Positioning and Benchmarking:

It is a national key clinical specialty, a vice-chairman unit of the Physical Medicine and Rehabilitation Branch of the Chinese Medical Association (Professor Wei Quan was elected in 2025), and a joint organizer of the Advanced Physical Therapist Certification Course of the Asia-Pacific Association for Cardiopulmonary Rehabilitation. The center's three specialties—physical therapy, occupational therapy, and prosthodontics—have all passed international accreditations (WCPT/WFOT/ISPO). In 2025, the team hosted the 6th Annual Meeting of the Physical Therapy Professional Committee of the Chinese Association of Rehabilitation Medicine, inviting 216 domestic and international experts to conduct 233 academic lectures, attracting over a thousand representatives from 22 provinces, autonomous regions, municipalities, and Hong Kong and Macau to attend offline.

Digestive Rehabilitation is an interdisciplinary subspecialty based on the National Key Clinical Specialty of Rehabilitation Medicine and the National Key Discipline of Gastroenterology. The Rehabilitation Medicine Center has consistently ranked first in national reputation among Fudan University specialties for many years; the Department of Gastroenterology ranks third nationally in terms of hospital science and technology value and sixth nationally among Fudan University specialties. The Digestive Rehabilitation specialization integrates the strengths of these two disciplines, focusing on rehabilitation interventions for functional gastrointestinal disorders, inflammatory bowel diseases, and functional disorders following digestive surgery and pancreatitis. It is positioned as a clinical demonstration center for functional rehabilitation of digestive diseases in Southwest China.

Historical Origins and Spiritual Inheritance:

West China Rehabilitation can be traced back to the physical factor therapy at Cunren Hospital in 1929, and the Department of Physical Therapy was established in 1951; the Gastroenterology Professional Group was established in 1956. The field of digestive rehabilitation has been gradually systematized under the promotion of Professor Liu Ling (postdoctoral fellow at Johns Hopkins University, deputy head of the Inflammatory Bowel Disease Group of the Gastroenterology Branch of the Chinese Medical Association) and others.

Core business operational efficiency:

The Rehabilitation Medicine Center has 211 beds and 283 staff members, comprising 23 subspecialties, 12 treatment departments, and 5 functional laboratories. The Department of Gastroenterology sees over 200,000 outpatients annually and performs over 150,000 endoscopic procedures annually. The Integrated Traditional Chinese and Western Medicine Digestive Rehabilitation Clinic, led by Professor Li Ning, sees over 2,000 outpatients annually.

Discipline Positioning and Benchmarking:

It is a National Key Clinical Specialty (Rehabilitation Medicine), a National Key Discipline of the Ministry of Education (Gastroenterology), and a standing committee unit of the Chinese Rehabilitation Medicine Gastroenterology Rehabilitation Committee. Professor Liu Ling serves as a member of the Youth Committee of the Gastroenterology Branch of the Chinese Medical Association, the deputy leader of the Inflammatory Bowel Disease Group, and a member of the Gastroenterology Committee of the Sichuan Medical Association. Professor Li Ning is a leading traditional Chinese medicine doctor in Sichuan Province.

The Department of Pain Management at West China Hospital of Sichuan University is a National Key Clinical Specialty (approved in 2014), a vice-chairman unit of the Pain Management Branch of the Chinese Medical Association, the chairman unit of the Pain Medicine Committee of the Sichuan Medical Association, and the Sichuan Provincial Pain Professional Quality Control Center. The department is characterized by its ultrasound-guided chronic pain diagnosis and treatment and visualized minimally invasive interventional techniques. It is nationally leading in the construction of "pain-free hospitals" and comprehensive pain management, positioning itself as the largest and most technologically advanced pain treatment center in Southwest China and a core base for standardized training of pain specialists nationwide. The department was among the first in China to promote and popularize ultrasound therapy, with over 48,000 outpatient visits and over 4,300 inpatient admissions annually.

Historical Origins and Spiritual Inheritance:

The Department of Pain Management was first established as an outpatient clinic in April 1995, followed by an inpatient ward in February 2003. It was formally established as a department in 2013 and approved as a National Key Clinical Specialty by the Ministry of Health (National Health Commission) in 2014. Starting as an outpatient clinic, under the leadership of Professor Liu Hui, the department has gradually developed into a nationally renowned pain management center with four inpatient wards (main campus, Tianfu campus, Shangjin campus, and the Fifth Provincial Hospital) and 101 open beds.

Core business operational efficiency:

The department currently has 2-3 professors/chief physicians, 4-5 associate professors/associate chief physicians, 5-7 attending physicians specializing in pain management, 4 master's degree supervisors, and 40-50 rotating resident physicians. It also recruits 30-40 visiting scholars annually. The pain management outpatient clinic is equipped with a diagnostic room, invasive treatment room, non-invasive treatment room, and infrared thermography room, and is equipped with advanced equipment such as next-generation nerve stimulators, ultrasound, radiofrequency ablation devices, plasma therapy devices, and ozone therapy devices. In 2024, the department performed over 4,000 interventional surgeries guided by CT or C-arm. The annual outpatient volume exceeds 48,000 visits, and the annual inpatient volume exceeds 4,300.

Discipline Positioning and Benchmarking:

It is a National Key Clinical Specialty (established in 2014), a vice-president unit of the Pain Medicine Branch of the Chinese Medical Association, a chairman unit of the Pain Medicine Committee of the Sichuan Medical Association, and the Sichuan Provincial Pain Professional Quality Control Center. Professor Liu Hui serves as the vice president of the Pain Medicine Branch of the Chinese Medical Association, a standing committee member of the Pain Medicine Branch of the Chinese Medical Association, the chairman of the Pain Medicine Committee of the Sichuan Medical Association, the director of the Sichuan Provincial Pain Professional Quality Control Center, a high-level overseas returnee talent in Sichuan Province, and a leading talent in the Sichuan Provincial 2024 "Health and Wellness Talents Program" .

The Rehabilitation Medicine Center of West China Hospital, Sichuan University, is a national key clinical specialty and the chairman unit of the Physical Medicine and Rehabilitation Branch of the Chinese Medical Association, as well as the vice-president unit of the Chinese Association of Rehabilitation Medicine. For many consecutive years, the center's rehabilitation medicine program has ranked first in the national reputation rankings of Fudan University's specialized programs. Oncology rehabilitation, as a cutting-edge sub-specialty among the center's 23 sub-specialties, is specifically undertaken by the Oncology Rehabilitation Research Laboratory (Director: Associate Researcher Xia Yong, Deputy Director: Associate Professor Zhu Siyi). It has developed systematic programs in areas such as functional rehabilitation after tumor surgery and radiotherapy/chemotherapy, comprehensive treatment of lymphedema, and exercise intervention for cancer-related fatigue. It is one of the distinctive sub-specialty directions of the first full-time undergraduate rehabilitation program in mainland China.

Historical Origins and Spiritual Inheritance:

The history of West China Rehabilitation Medicine can be traced back to the physical factor therapy that began at Cunren Hospital in 1929. In December 1951, West China Union University Hospital established the Department of Physical Therapy and the Department of Occupational Therapy, marking the formal establishment of West China Rehabilitation Medicine. In September 1989, the Rehabilitation Medicine Center was officially established. Tumor rehabilitation has been listed as one of the cutting-edge areas since the establishment of the center's subspecialty system, and it has been further strengthened after becoming a national key clinical specialty in 2013.

Core business operational efficiency:

The center has 211 beds and 283 staff members, including 46 senior professionals, 51 PhDs, and 35 postdoctoral fellows. The center comprises four wards, twenty-three subspecialties, twelve treatment departments, five research laboratories, and seven specialized centers. The Tumor Rehabilitation Research Laboratory is one of the five dedicated research laboratories, and the center also offers an outpatient clinic specializing in tumor rehabilitation. Associate Researcher Xia Yong serves as a doctoral supervisor and postdoctoral fellow supervisor, and is one of the center's five doctoral supervisors. Associate Professor Zhu Siyi, as a master's supervisor, participates in research and clinical work in the field of tumor rehabilitation.

Discipline Positioning and Benchmarking:

It is a national key clinical specialty, the chairman unit of the Physical Medicine and Rehabilitation Branch of the Chinese Medical Association, and the vice-president unit of the Chinese Association of Rehabilitation Medicine. The center has a key laboratory for rehabilitation medicine in Sichuan Province, and its three specialties—physical therapy, occupational therapy, and prosthodontics—have all passed international accreditation (WCPT/WFOT/ISPO). The center closely collaborates with more than 30 departments, including the Department of Oncology, to provide patients with advanced, precise, comprehensive, and personalized rehabilitation assessment and treatment services through early rehabilitation intervention. It has formed a full-cycle management model of "interdisciplinary outpatient rehabilitation consultation → outpatient rehabilitation treatment → perioperative/perioperative rehabilitation treatment → rehabilitation follow-up → home rehabilitation".

The Rehabilitation Medicine Center of West China Hospital, Sichuan University, is a national key clinical specialty and a vice-chairman unit of the Physical Medicine and Rehabilitation Branch of the Chinese Medical Association (Professor Wei Quan was elected in 2025), as well as a vice-president unit of the Chinese Association of Rehabilitation Medicine. The center's rehabilitation medicine program has consistently ranked first in the national reputation rankings of Fudan University specialties for many years. Critical care rehabilitation, as the core direction of the "organ rehabilitation" sub-specialty among the center's 23 specialties, is specifically undertaken by the Department of Cardiopulmonary and Critical Care Physical Therapy (with Professor Yu Pengming as the technical head and Yang Mengxuan as the department head). It holds a leading position nationwide in the fields of early rehabilitation intervention in the ICU, peri-extubation physical therapy, and functional maintenance of critically ill patients. It is one of the earliest units in mainland China to systematically carry out clinical practice and standardized training in critical care rehabilitation.

Historical Origins and Spiritual Inheritance:

The history of West China Rehabilitation can be traced back to physical factor therapy initiated at Cunren Hospital in 1929. In December 1951, West China Union University Hospital established a Department of Physical Therapy and a Department of Occupational Therapy, marking the formal establishment of West China Rehabilitation. In September 1989, the Rehabilitation Medicine Center was officially established. Professor He Chengqi, as one of the earliest experts and advocates in China to engage in critical care rehabilitation research, has led his team in conducting critical care rehabilitation practice in neurosurgery since 2008, gradually building the West China critical care rehabilitation model. The Department of Cardiopulmonary and Critical Care Physical Therapy was established in 2007, with Professor Yu Pengming as the technical head. It is one of the earliest professional teams in China to systematically conduct cardiopulmonary and critical care physical therapy.

Core business operational efficiency:

The center has 211 beds and 283 staff members, including 46 senior professionals, 51 PhDs, and 35 postdoctoral fellows. The Cardiopulmonary and Critical Care Physical Therapy Department has 18 physical therapists, including 3 senior professionals, 7 intermediate professionals, 2 PhDs, and 16 Master's degree holders. It offers four basic subspecialties: respiratory physical therapy, cardiac physical therapy, critical care physical therapy, and perioperative physical therapy, as well as a digital rehabilitation specialization. The critical care rehabilitation team works closely with departments such as critical care medicine, neurosurgery, neurology, cardiology, cardiac surgery, burn surgery, and the lung cancer center. Since 2008, the team has treated more than 2,000 patients in neurosurgery; intervened in more than 1,100 patients in neurology in the past five years; and intervened in 590 lung cancer patients in the ICU in the past two years. This has effectively shortened patients' hospital stays, improved their functional status, and enhanced their ability to live independently and their quality of life.

Discipline Positioning and Benchmarking:

It is a national key clinical specialty, a vice-chairman unit of the Physical Medicine and Rehabilitation Branch of the Chinese Medical Association, and a vice-president unit of the Chinese Association of Rehabilitation Medicine. The center has a key laboratory for rehabilitation medicine in Sichuan Province, and its three specialties—physical therapy, occupational therapy, and prosthodontics—have all passed international accreditation (WCPT/WFOT/ISPO). Professor Yu Pengming serves as the chairman of the Advanced Physical Therapist Certification Course of the Asia-Pacific Association for Cardiopulmonary Rehabilitation, and Professor Wei Quan serves as a standing committee member of the Critical Care Rehabilitation Committee of the Chinese Association of Rehabilitation Medicine. The Department of Cardiopulmonary and Critical Care Physical Therapy at the Center undertakes undergraduate and master's teaching in physical therapy at the School of Rehabilitation Medicine, West China School of Clinical Medicine, Sichuan University, as well as basic and clinical research related to cardiopulmonary and critical care physical therapy.

The Rehabilitation Medicine Center of West China Hospital, Sichuan University, is a national key clinical specialty and a vice-chairman unit of the Physical Medicine and Rehabilitation Branch of the Chinese Medical Association (Professor Wei Quan was elected in 2025), as well as a vice-president unit of the Chinese Association of Rehabilitation Medicine. The center's rehabilitation medicine program has consistently ranked first in the national reputation rankings of Fudan University specialties for many years. Critical care rehabilitation, as the core direction of the "organ rehabilitation" sub-specialty among the center's 23 specialties, is specifically undertaken by the Department of Cardiopulmonary and Critical Care Physical Therapy (with Professor Yu Pengming as the technical head and Yang Mengxuan as the department head). It holds a leading position nationwide in the fields of early rehabilitation intervention in the ICU, peri-extubation physical therapy, and functional maintenance of critically ill patients. It is one of the earliest units in mainland China to systematically carry out clinical practice and standardized training in critical care rehabilitation.

Historical Origins and Spiritual Inheritance:

The history of West China Rehabilitation can be traced back to physical factor therapy initiated at Cunren Hospital in 1929. In December 1951, West China Union University Hospital established a Department of Physical Therapy and a Department of Occupational Therapy, marking the formal establishment of West China Rehabilitation. In September 1989, the Rehabilitation Medicine Center was officially established. Professor He Chengqi, as one of the earliest experts and advocates in China to engage in critical care rehabilitation research, has led his team in conducting critical care rehabilitation practice in neurosurgery since 2008, gradually building the West China critical care rehabilitation model. The Department of Cardiopulmonary and Critical Care Physical Therapy was established in 2007, with Professor Yu Pengming as the technical head. It is one of the earliest professional teams in China to systematically conduct cardiopulmonary and critical care physical therapy.

Core business operational efficiency:

The center has 211 beds and 283 staff members, including 46 senior professionals, 51 PhDs, and 35 postdoctoral fellows. The Cardiopulmonary and Critical Care Physical Therapy Department has 18 physical therapists, including 3 senior professionals, 7 intermediate professionals, 2 PhDs, and 16 Master's degree holders. It offers four basic subspecialties: respiratory physical therapy, cardiac physical therapy, critical care physical therapy, and perioperative physical therapy, as well as a digital rehabilitation specialization. The critical care rehabilitation team works closely with departments such as critical care medicine, neurosurgery, neurology, cardiology, cardiac surgery, burn surgery, and the lung cancer center. Since 2008, the team has treated more than 2,000 patients in neurosurgery; intervened in more than 1,100 patients in neurology in the past five years; and intervened in 590 lung cancer patients in the ICU in the past two years. This has effectively shortened patients' hospital stays, improved their functional status, and enhanced their ability to live independently and their quality of life.

Discipline Positioning and Benchmarking:

It is a national key clinical specialty, a vice-chairman unit of the Physical Medicine and Rehabilitation Branch of the Chinese Medical Association, and a vice-president unit of the Chinese Association of Rehabilitation Medicine. The center has a key laboratory for rehabilitation medicine in Sichuan Province, and its three specialties—physical therapy, occupational therapy, and prosthodontics—have all passed international accreditation (WCPT/WFOT/ISPO). Professor Yu Pengming serves as the chairman of the Advanced Physical Therapist Certification Course of the Asia-Pacific Association for Cardiopulmonary Rehabilitation, and Professor Wei Quan serves as a standing committee member of the Critical Care Rehabilitation Committee of the Chinese Association of Rehabilitation Medicine. The Department of Cardiopulmonary and Critical Care Physical Therapy at the Center undertakes undergraduate and master's teaching in physical therapy at the School of Rehabilitation Medicine, West China School of Clinical Medicine, Sichuan University, as well as basic and clinical research related to cardiopulmonary and critical care physical therapy.

This is a key specialty of organ transplantation designated by the National Health Commission and a training base for human organ transplantation in Sichuan Province. It relies on the Key Laboratory of Transplantation Engineering and Transplantation Immunology of the Ministry of Health (approved in 2002, formerly the Sichuan Provincial Key Laboratory established in 1999), focusing on basic and clinical translational research in transplantation immunology, xenotransplantation donor development, and stem cell therapy. The laboratory was founded by Professor Li Youping, with Professor Cheng Jingqiu as the discipline leader and Professor Yang Jiayin as the director. The Liver Transplantation Research Laboratory has four professors/doctoral supervisors, and has received over 15 million RMB in various grants. Its research findings have been published in top journals such as the Journal of Hepatology, Hepatology, and the American Journal of Transplantation.

1. Historical Origins and Spiritual Inheritance

West China Hospital's organ transplantation program began in 1979, completing the first liver transplant in Southwest China. In 2013, the Organ Transplantation Center was formally established, and it has since completed over 10,000 major organ transplant surgeries, covering multiple organ types including liver, kidney, heart, lung, pancreas, and larynx. It is one of the few centers in China capable of performing multi-organ cluster transplants. In the field of head and neck organ transplantation, Professor Chen Fei's team in the Department of Otolaryngology-Head and Neck Surgery completed Asia's first allogeneic larynx-trachea-thyroid gland transplant and the world's first multi-organ cluster (5 organs) transplant for hypopharyngeal and esophageal cancer in 2023, pushing West China Hospital's multi-organ transplantation to the international forefront. Inheriting the transplantation concept of "multidisciplinary collaboration and tackling complex end-stage multi-organ failure", and relying on a multidisciplinary team (MDT), we have continuously broken through the taboos of combined transplantation technology, and have successively completed landmark surgeries such as Asia's first laryngeal-tracheal-thyroid transplant and the world's first five-organ cluster transplant for hypopharyngeal esophageal cancer.

1. Core Business Operation Efficiency

The hospital has performed over 10,000 organ transplants, ranking among the top two in the country, and has been the number one center in China for living donor kidney transplants for 13 consecutive years. It has performed over 1,700 liver transplants with a 5-year survival rate of nearly 80%, and 7 laryngeal transplants, making it the world's largest treatment center. The world's first combined liver-laryngeal transplant was also performed by the West China team. In 2023, the Head and Neck Complex Tumor Surgery Center was established, with Professor Chen Fei as its director, specializing in multi-organ cluster transplantation and repair/reconstruction for advanced head and neck malignancies. We routinely perform combined liver and kidney, combined pancreas and kidney, combined liver and intestine, combined heart and lung, and laryngeal multi-organ cluster transplants; we have established an integrated MDT system encompassing donor retrieval, multi-organ remodeling, simultaneous multi-organ transplantation surgery, ECMO/CRRT perioperative life support, combined immunosuppressive regulation, and long-term follow-up; our long-term survival rate in combined organ transplantation has reached leading levels in China and advanced levels internationally, making us a core base for the treatment of complex and critically ill patients undergoing combined transplantation in China.

1. Discipline Positioning and National/Global Benchmarking

It is a key specialty of organ transplantation designated by the National Health Commission and a training base for human organ transplantation in Sichuan Province. It serves as a national-level quality control and training platform for organ transplantation, relying on the Sichuan Provincial Key Laboratory of Xenotransplantation and Regeneration. It is a leading center for multi-organ cluster transplantation in China, at the forefront globally in abdominal multi-organ combined transplantation and head and neck multi-tissue organ cluster transplantation. In transplant immunology, multi-organ donor protection, and combined transplant rejection prevention, it benchmarks against top transplant centers in Europe and America, undertaking the task of referring and treating patients with complex multiple organ failure in western China.

412737

The center fully leverages the comprehensive strengths of West China Hospital, ranked second in the nation, integrating the expertise of multiple disciplines, including Respiratory and Critical Care Medicine (a key discipline of the Ministry of Education), Anesthesiology (ranked first in the nation for ten consecutive years), ICU, and Rehabilitation (all national key clinical specialties). The monograph "Clinical Lung Transplantation" was edited by experts from the center (a major national publishing project during the 14th Five-Year Plan period), and the center's experts became the first Chinese experts to deliver a keynote speech at the International Conference on Heart and Lung Transplantation.

1. Historical Origins and Spiritual Inheritance

The West China Lung Transplant Center is built upon the West China Thoracic Surgery Department (established in 1954, one of the birthplaces of thoracic surgery in China). In 2007, it successfully performed the first allogeneic sequential double lung transplant in western China, making it the earliest center in Southwest China with lung transplant qualifications. The center is led by the Thoracic Surgery Department and comprises a multidisciplinary team from the Department of Respiratory and Critical Care Medicine, Anesthesiology, ICU, Rehabilitation Department, and Clinical Nutrition Department. Its core philosophy is "Minimally Invasive and Multidisciplinary Collaboration"—from traditional open incisions to the world's first thoracoscopic sequential double lung transplant, it consistently strives to minimize patient trauma through minimally invasive techniques. Inheriting the transplantation philosophy of "minimally invasive breakthroughs, multidisciplinary collaboration, and comprehensive support for critical cases," the discipline restarted the lung transplantation project in 2016 and established a stable lung transplantation MDT system.

1. Core Business Operation Efficiency

Led by the Department of Thoracic Surgery, the center integrates the Departments of Respiratory and Critical Care Medicine, Intensive Care Medicine, Anesthesiology, Rehabilitation Medicine, and Organ Transplantation Laboratory to form an integrated diagnosis and treatment chain encompassing donor lung acquisition, preoperative recipient assessment, intraoperative ECMO life support, postoperative rejection/infection control, and long-term rehabilitation follow-up. It routinely performs single lung transplantation, sequential double lung transplantation, and minimally invasive lung transplantation. The center boasts a leading success rate in perioperative treatment of severe end-stage lung disease in China, and its medium- and long-term post-transplant survival rates are comparable to those of top-tier lung transplant centers in the country.

1. Discipline Positioning and National/Global Benchmarking

This national-level organ transplant qualification platform, relying on key disciplines of the Ministry of Education and key clinical specialties of the National Health Commission, boasts a thoracic surgery department that has ranked 4th in the Fudan University specialty rankings for nine consecutive years (1st among general hospitals). It was among the first in the world to perform fully thoracoscopic sequential double lung transplants and ECMO-assisted lung transplants, achieving top-ranking surgical success rates and long-term postoperative survival rates nationwide. In recent years, it has performed 10-20 lung transplants annually and has a professional lung transplant evaluation and postoperative management team. It possesses unique regional advantages in lung transplantation for end-stage lung disease, pneumoconiosis, and connective tissue disease-related interstitial lung disease in high-altitude areas, and serves as a core base for clinical lung transplantation, research, and talent training in Southwest China.

Relying on the West China Department of Hepatobiliary Surgery (a national key discipline and a national key clinical specialty), the department has established a liver transplant center, a key laboratory for transplantation engineering and transplantation immunology under the National Health Commission, and a liver transplantation research laboratory (covering an area of over 300 square meters). The research laboratory focuses on DCD donor liver quality assessment, islet transplantation and hepatocyte transplantation, and the development of novel multi-organ preservation solutions. It has received a total of over 15 million yuan in various grants, and its achievements have been published in top journals such as the Journal of Hepatology, Hepatology, and the American Journal of Transplantation.

1. Historical Origins and Spiritual Inheritance

West China Liver Transplant Center began in 1979, performing the third clinical liver transplant in China and the first in western China. Under the guidance of Professor Yan Linan and other senior experts, it completed the first adult living donor liver transplant in mainland China in 2001, making it one of the earliest centers in China to systematically perform living donor liver transplantation, pioneering the field in China. Its core spirit is condensed as "daring to be the first and using technology to benefit the people"—from the first case in western China to the first living donor liver transplant in mainland China, and then to robotic liver harvesting, it has consistently expanded the source of donor livers and reduced donor injury through technological innovation. It inherits the transplantation discipline's spirit of "tackling critical illnesses, ensuring safe donors, and managing long-term chronic diseases."

1. Core Business Operation Efficiency

The largest transplant center in western China has performed over 2,500 liver transplants of various types, including over 600 living donor liver transplants and over 200 infant liver transplants (including the lightest infant liver transplant in China). The 5-year survival rate for benign liver disease liver transplants is among the leading international standards. We have completed over 100 cases of ex vivo liver resection combined with autologous liver transplantation, which is internationally recognized as the most difficult and complex surgical procedure in this specialty. Our procedures include living donor liver transplantation, split liver transplantation, DCD donor liver transplantation, autologous liver transplantation, and multi-organ transplantation. The 5-year survival rate for recipients of benign end-stage liver disease is nearly 80%, reaching international advanced standards. We have a complete transplant MDT team covering the entire chain of preoperative assessment, surgery, perioperative ICU monitoring, long-term immunosuppression follow-up, and donor safety assurance.

1. Discipline Positioning and Benchmarking

It is a national-level core platform for organ transplantation, relying on national-level scientific research facilities such as the National Key Laboratory of Biological Therapy; it is a benchmark center for living donor liver transplantation in China, and it benchmarks against top international transplantation centers in the fields of complex vascular/bile duct reconstruction, high-risk and critically ill recipients, pediatric liver transplantation, and hydatid worm autologous liver transplantation. It is a clinical, scientific research, and talent training base for organ transplantation in western China.

Based at the Institute of Urology-Kidney Transplantation Research Laboratory (the first research institute at West China Hospital of Sichuan University), the center focuses on cutting-edge research areas such as the mechanism and prevention of renal ischemia-reperfusion injury, the impact of immunosenescence on kidney transplant prognosis, the rejection and adaptation mechanism of ABO blood type incompatible kidney transplantation, HBsAg+ donor kidney transplantation, and post-transplant immune monitoring. In the past five years, the center has led one key research and development project funded by the Ministry of Science and Technology and eight National Natural Science Foundation of China projects, publishing over 70 SCI papers in journals such as *Nature Communications*, *Kidney International*, *American Journal of Transplantation*, and *Clinical Infectious Diseases*. The center has also authored and compiled the *Clinical Guidelines for Living Donor Kidney Transplantation* and the *Technical Specifications for Living Donor Kidney Transplantation*, providing "West China Standards" for the standardized development of kidney transplantation nationwide.

1. Historical Origins and Spiritual Inheritance

West China Kidney Transplant Center was established in 1979 and completed the first allogeneic kidney transplant in Southwest my country, making it one of the earliest institutions in China to conduct kidney transplantation work. The center performed its first kidney transplant surgery in January 1979, and successfully performed the first kidney transplant in Southwest China in 1978. The center consists of a urology kidney transplant subspecialty team, a nephrology team, and a kidney transplant nursing team. It pioneered an integrated medical and nursing management model of "urology-nephrology-nursing" nationwide, practicing the innovative concepts of "doctors following patients" and "interdisciplinary integration of internal and external disciplines," achieving full-cycle management of kidney transplant patients during the perioperative, recovery, and complication periods. Professor Lin Tao, the discipline leader, is a standing committee member of the Organ Transplantation Branch of the Chinese Medical Association, deputy head of the Kidney Transplantation Group of the Transplantation Branch of the Chinese Medical Doctor Association, and chairman of the Sichuan Provincial Organ Transplantation Committee. He is an academic and technical leader in Sichuan Province and a high-level overseas talent. The Kidney Transplantation Center was established in conjunction with the Department of Urology at West China Hospital (a national key clinical specialty), inheriting the transplantation discipline's spirit of "rigorous and pragmatic approach, tackling critical illnesses." It is one of the earliest centers in China to perform kidney transplantation and the birthplace of living donor kidney transplantation in China.

1. Core Business Operation Efficiency

The hospital has completed over 7,000 kidney transplants to date; ranked first in the country for living donor kidney transplants for 11 consecutive years; ranked first in the country for ABO incompatible kidney transplants; ranked first in the country for laparoscopic kidney harvesting; and ranked first in the country for robotic-assisted kidney transplants. The annual total number of transplants has consistently ranked among the top three in the country; the 1-year survival rate for transplant recipients is approximately 99%, and the 5-year survival rate is approximately 96%, with the longest-surviving transplanted kidney exceeding 40 years, significantly surpassing the standards of the UNOS database in the United States and reaching international leadership; and has established a comprehensive multidisciplinary team (MDT) system encompassing donor preoperative evaluation, transplant surgery, perioperative ICU monitoring, immunosuppression management, and long-term follow-up, while also building a post-transplant follow-up network in the Sichuan-Tibet region.

1. Discipline Positioning and National/Global Benchmarking

It is a key specialty of organ transplantation designated by the National Health Commission, a training base for human organ transplantation in Sichuan Province (with qualifications to train physicians specializing in liver and kidney transplantation), a national-level organ transplantation demonstration center, and relies on national-level scientific research platforms related to organ transplantation. It is a benchmark center for living donor kidney transplantation and ABO incompatible kidney transplantation in China. Its minimally invasive kidney transplantation and robotic kidney transplantation technologies have reached international advanced levels. In the fields of donor safety assurance and precise prevention and control of transplant rejection, it benchmarks against top transplantation centers in Europe and the United States, serving as a core base for clinical organ transplantation, scientific research, and talent training in Southwest China.

The Rare Disease Research Institute was established in 2020, relying on the "Frontiers in Molecular Disease Networks" and with an investment of 150 million yuan. Centered on the "China 100,000 Rare Disease Patient Whole Genome Sequencing Project," the institute systematically conducts research and development on the molecular etiology of rare diseases, gene therapy, nucleic acid drugs, and AI-powered intelligent decision-making systems. The center's expert team has secured 34 research projects with a total funding of over 85 million yuan, and published 159 related articles (128 SCI papers) with an impact factor of 483.954. A rare disease collaboration has been established with the University of Birmingham, UK, forming the West China-Birmingham Joint Institute for Health and Biomedical Information.

1. Historical Origins and Spiritual Inheritance

West China Hospital, as a national-level center for the diagnosis and treatment of complex, critical, and severe illnesses in western my country, established a consultation center for complex diseases as early as 2009, pioneering a multidisciplinary consultation model for complex diseases nationwide. In 2016, it formally established a rare disease diagnosis and treatment center, which was transformed into a rare disease diagnosis and treatment and research center with its own organizational code in 2021. In June 2022, it implemented a departmental-level structure, with the complex disease consultation center and the rare disease diagnosis and treatment and research center under its umbrella. It integrates 37 clinical and medical technology departments across the hospital, constructing a multidisciplinary team (MDT) system for complex and critical illnesses, breaking down departmental barriers, and practicing the spirit of "one case, one policy; multidisciplinary collaborative efforts" in diagnosis and treatment. The core spirit is condensed into "Making the 'Rare' Visible"—addressing the dilemma that rare disease patients typically take more than four years to be diagnosed, the hospital breaks down departmental barriers through an intensive model, providing efficient diagnosis and treatment channels for patients with difficult, complex, critical, and rare diseases. West China Hospital, with its century-old tradition of "high moral character, professional excellence, pragmatism, and innovation," has long undertaken the task of providing comprehensive treatment for difficult and critical diseases in western China.

1. Core Business Operation Efficiency

The center offers outpatient services for complex and rare diseases via multidisciplinary team (MDT) consultations, remote multidisciplinary consultations, and a green channel for critical and difficult cases. It brings together 37 clinical and medical technology departments, 7-10 research teams, and hundreds of experts, including 45 chief scientists. It has cumulatively diagnosed over 4,000 rare diseases and established 31 specialized rare disease clinics. The center offers 72 types of multidisciplinary team (MDT) consultations, with participating physicians all holding associate professor or higher titles. Rare disease specialist outpatient clinics average 102 visits per week, with over 4,000 rare disease diagnoses. There are 38 online/offline rare disease MDT teams, covering 51 diseases listed in the National Rare Disease Catalogue, with confirmed cases involving 90 diseases within the catalogue. The consultation service for rare and difficult cases has served more than 35,000 patients. It receives complex and difficult cases with unclear diagnoses and ineffective treatments referred from all over the country, especially from the southwest region, which has significantly shortened the average diagnosis cycle for rare diseases. It has also established an integrated closed-loop system that combines clinical treatment, gene testing, biobank, long-term follow-up, and rehabilitation management.

1. Discipline Positioning and National/Global Benchmarking

It is a national-level center for the diagnosis and treatment of rare, critical, and severe diseases in western China; relying on national-level research platforms such as the State Key Laboratory of Biological Therapy, the National Major Science and Technology Infrastructure for Translational Medicine, and the Precision Medicine Platform; a benchmark platform for rare disease MDT in China, leading the country in rare disease genome research among multi-ethnic populations and integrated treatment of rare, critical, and severe diseases; in 2021, it won the first "Golden Snail Award" for contribution to rare disease medicine (the first award in the field of rare diseases in China). It conducts joint research on rare diseases with international institutions such as the University of Birmingham in the UK, aiming to become a top international center for the diagnosis and treatment of rare diseases, and is a core hub for clinical practice, scientific research, and talent training of rare and difficult diseases in western China.

The Department of Oncology at West China Hospital of Sichuan University is a national key discipline of the Ministry of Education and a key clinical specialty of the National Health and Family Planning Commission. It is a national clinical trial base for new anti-tumor drugs and the largest comprehensive oncology treatment center in western China. The department is characterized by its pioneering leadership in molecularly targeted therapy for tumors and its comprehensive treatment of abdominal tumors. For many consecutive years, it has ranked among the top ten oncology departments in China. It was one of the first institutions in China to establish a professional committee on molecularly targeted therapy for tumors and is positioned as a core center for clinical oncology, scientific research, and new drug translational research in western China.

Historical Origins and Spiritual Inheritance:

The Department of Oncology at West China Hospital was established under the auspices of the West China Hospital Cancer Center, which is the largest comprehensive cancer treatment center in Southwest China. Under the leadership of Professor Bi Feng (recipient of the National Science Fund for Distinguished Young Scholars and the first chairman of the Committee on Molecular Targeted Therapy for Tumors of the Chinese Society for Biomedical Engineering), the department established the Chinese Committee on Molecular Targeted Therapy for Tumors in 2008. Professor Bi Feng served as the chairman of the Chinese Conference on Molecular Targeted Therapy for Tumors for ten consecutive years, becoming a national leader in the field.

Core business operational efficiency:

The center is divided into subspecialty wards, including abdominal oncology, thoracic oncology, head and neck oncology, and oncology immunotherapy. The abdominal oncology department is currently the largest comprehensive abdominal oncology treatment center in Taiwan, with over 100 medical staff, including 8 professors, 8 associate professors, 5 doctoral supervisors, and 7 master's supervisors. The main ward has 140 beds, and the Shangjin branch has 40 beds. The thoracic oncology department has 130 medical staff, including 10 professors/chief physicians, 4 doctoral supervisors, and 8 master's supervisors. The department has undertaken and completed more than 80 clinical trials of new drugs and therapies at home and abroad, and has served as the lead unit for national multi-center new drug clinical trial projects many times (such as dolafinib mesylate, cabazitaxel, and dianticon sodium).

Discipline Positioning and Benchmarking:

It is a key discipline of the Ministry of Education, a key clinical specialty of the Ministry of Health, and a national clinical trial base for new anti-tumor drugs. It is the only comprehensive hospital oncology center that ranks among the top 10 in the country for oncology. Professor Bi Feng serves as the chairman of the Committee on Molecular Targeted Therapy for Tumors of the Chinese Society for Biomedical Engineering, the vice chairman of the Oncology Branch of the Chinese Association of Research Hospitals, the vice chairman of the Expert Committee on Biliary Tract Tumors of the Chinese Society of Clinical Oncology, the chief expert of health and wellness in Sichuan Province, and a recipient of the National Science Fund for Distinguished Young Scholars. The center is affiliated with the State Key Laboratory of Biological Therapy and undertakes many major national projects, including the National 973 Program, the National 863 Program, the 11th to 13th Five-Year Plans, and the National Natural Science Foundation of China.

The Department of Gastroenterology at West China Hospital of Sichuan University is a National Key Discipline and a National Key Clinical Specialty of the Ministry of Education. It serves as the Southwest China Center for the Diagnosis and Treatment of Complex and Critical Digestive Diseases and a national training base for gastrointestinal endoscopy designated by the Ministry of Health. The department is renowned for its diagnosis and treatment of gastrointestinal, hepatic, and biliary and pancreatic diseases, ranking third nationally in hospital science and technology evaluation and sixth nationally among Fudan University specialties. The current department director, Professor Tang Chengwei, received the World Gastroenterology Organization (WGO) "Master" title in 2025, the only recipient from East Asia this year, and the third Chinese gastroenterologist to receive this honor, following Professor Xiao Shudong and Academician Fan Daiming.

Historical Origins and Spiritual Inheritance :

The Department of Gastroenterology was established in the 1970s by senior experts such as Zhang Guangru, Zhang Jianhu, Zhang Shangzhi, Bai Chuanxian, and Chen Dezhen. Professor Zhang Shangzhi, as one of the main founders, served as the chairman of the first Sichuan Provincial Gastroenterology Professional Committee and a member of the second to fourth committees of the Chinese Society of Gastroenterology. He received numerous awards, including the Outstanding Teacher Award from the Ministry of Health's affiliated higher education institutions. Professors Ouyang Qin and Chen Dezhen dedicated 56 and 63 years respectively to medical practice and teaching, making significant contributions to the development of the discipline. The department consistently adheres to the principle of "providing the best medical services to those suffering from digestive system diseases," earning a renowned reputation in Southwest China and even nationwide.

Core business operational efficiency :

The department currently has 74 physicians (41 with senior professional titles), 168 nurses, and 23 postgraduate supervisors (11 of whom are doctoral supervisors). It has over 190 beds, with over 10,000 inpatients and outpatients annually, and over 240,000 outpatient visits annually. The affiliated gastrointestinal endoscopy center handles over 140,000 cases annually, offering advanced endoscopic techniques such as gastrointestinal motility monitoring, magnetically controlled capsule endoscopy, EUS, EMR/ESD, endoscopic hemostasis, and ERCP. The department has developed several subspecialties with West China Hospital characteristics, including cirrhosis and liver cancer, inflammatory bowel disease, non-variceal gastrointestinal bleeding, acute pancreatitis, and endoscopic and interventional diagnosis and treatment.

Discipline Positioning and Benchmarking :

It is a National Key Discipline of the Ministry of Education (2007) and a Key Clinical Specialty of the Ministry of Health (2010). Professor Tang Chengwei currently serves as the Chairperson of the Gastroenterology Branch of the Chinese Medical Association (12th term). In the past five years, the department has undertaken more than 40 research projects, including National Natural Science Foundation of China projects, Ministry of Science and Technology key projects, and international cooperation projects. It has won two provincial and ministerial-level scientific research achievement awards, published more than 370 papers (more than 280 in SCI journals), including international authoritative journals such as Gastroenterology, Gut, Gastrointestinal Endoscopy, and Radiology, and edited more than 10 monographs.

The Department of Gastrointestinal Surgery at West China Hospital of Sichuan University is a national key discipline of the Ministry of Education and a key clinical specialty of the National Health Commission. It is the center for the diagnosis and treatment of complex gastrointestinal diseases in my country and the location of the Laparoscopic Surgery Training Institute of the Chinese Medical Association. Led by Professor Zhou Zongguang, a pioneer and standardizer of laparoscopic gastrointestinal surgery in my country, the department holds a leading position domestically in minimally invasive sphincter-preserving surgery for colorectal cancer, standardized radical gastrectomy for gastric cancer, and bariatric metabolic surgery.

Historical Origins and Spiritual Inheritance :

Established as an independent subspecialty in 1978, the Department of Gastrointestinal Surgery is one of the earliest surgical subspecialties established at West China Hospital. Starting as a gastrointestinal specialty group within the Department of General Surgery in the 1950s, it developed over several decades and formally established a specialized ward in 2000. Under the leadership of Professor Zhou Zongguang, the team pioneered laparoscopic TME (Transurethral Resection of the Intestine) ultra-low anterior rectal resection with sphincter preservation in 2000, and related achievements were incorporated into the guidelines of the European Association of Endoscopy (EAES) and the Japanese Society of Colorectal Cancer (JSCCR). Professor Zhou Zongguang drafted and formulated the first "Standardized Surgical Procedures for Laparoscopic Colorectal Tumors" in China (2001) and served as the chief editor of the national "Eleventh Five-Year Plan" textbook, "Surgery."

Core business operational efficiency :

The center currently has 170 beds and performs over 6,630 surgeries annually. The wards have one national-level talent, four doctoral supervisors, five master's supervisors, eight professors, and two associate professors. In the past four years (2021-2024), the average annual number of outpatient visits was 37,419, and the average annual number of inpatient discharges was 3,197. The center has subspecialties including gastric oncology, colorectal oncology, bariatric and metabolic surgery, hernia and abdominal wall surgery, inflammatory bowel disease, fistula, and gastrointestinal nutrition.

Discipline Positioning and Benchmarking :

It is a national key discipline of the Ministry of Education and a key clinical specialty of the National Health Commission, and the location of the Laparoscopic Surgery Training Institute of the Chinese Medical Association. Professor Zhou Zongguang serves as the Vice President of the Surgical Branch of the Chinese Medical Association, the Chairman of the Laparoscopic Surgery Professional Committee of the Chinese Medical Association, the Vice President of the International Association of Surgeons-Gastrointestinal Oncologists (IASGO), and the Chief Faculty (RCS) of Laparoscopic Surgery Training at the Royal College of Surgeons, UK.

The Department of Pancreatic Surgery at West China Hospital of Sichuan University is a national key discipline and a key discipline of the Ministry of Health. It is the largest and most academically influential center for the diagnosis, treatment, and research of pancreatic diseases in Southwest China. The department has consistently ranked third in the national ranking of hospital specialties by Fudan University for many years. Its landmark academic contributions include being the drafting unit of guidelines for the diagnosis and treatment of chronic pancreatitis and the integrated traditional Chinese and Western medicine treatment system for severe acute pancreatitis. It leads the way in minimally invasive surgery with total laparoscopic pancreaticoduodenectomy (LPD) and is positioned as one of the core bases for clinical practice, research, and talent training in pancreatic surgery in China.

Historical Origins and Spiritual Inheritance :

The Department of Pancreatic Surgery at West China Hospital was founded by Professor Zhang Zhaoda and other senior experts. After decades of development, 2024 marks Professor Zhang Zhaoda's 60th anniversary of his medical and teaching career. Under the leadership of Professors Liu Xubao and Tian Bole, the department has evolved from traditional open pancreatic surgery into a modern pancreatic surgery center characterized by minimally invasive techniques, organ preservation, and multidisciplinary team (MDT) approaches. Professor Liu Xubao, as the author of guidelines for the diagnosis and treatment of chronic pancreatitis, participated in the development of guidelines for severe acute pancreatitis published by the American Pancreatic Association (APA) and the International Pancreatic Association (IPA).

Core business operational efficiency :

The department currently has 34 physicians, including 7 professors, 10-11 associate professors/associate chief physicians, and 5 doctoral supervisors. Many physicians have studied or trained at renowned universities in the United States, Japan, Switzerland, Germany, and the United Kingdom. The department performs 3,600-4,000 surgeries annually on the liver, bile ducts, pancreas, spleen, and other organs. It has performed over 1,300 total laparoscopic pancreaticoduodenectomy (LPD) procedures, including over 160 LPD procedures combined with vascular resection and reconstruction (the largest number of such procedures performed by a single center globally). The LPD mortality rate is approximately 1%, reaching international advanced levels.

Discipline Positioning and Benchmarking :

It is a national key discipline and a key discipline of the Ministry of Health. Professor Tian Bole serves as a standing committee member of the Pancreatic Cancer Committee of the Chinese Anti-Cancer Association, deputy leader of the Pancreatic Group of the Gastroenterology Branch of the Chinese Medical Association, and chairman of the Pancreatic Cancer and Gastric Cancer Committee of the Sichuan Provincial Anti-Cancer Association. Professor Liu Xubao serves as the chairman-elect of the Pancreatic Cancer Committee of the Chinese Anti-Cancer Association and has been invited to participate in the development of guidelines by the International Society of Pancreatology. Professor Peng Bing serves as a Fellow of the American College of Surgeons (FACS) and a member of the Laparoscopic and Endoscopic Group of the Surgical Branch of the Chinese Medical Association. The discipline has consistently ranked third nationally in the Fudan University Specialty Reputation Ranking for many years.

10967412737

The Department of Colorectal Surgery at West China Hospital of Sichuan University is jointly operated by the Colorectal Oncology Center and the Department of Colorectal and Pelvic Floor Surgery. It is the first colorectal oncology center in Southwest China to integrate a multidisciplinary team encompassing surgery, internal medicine, radiotherapy, and interventional procedures. It is also one of the earliest national demonstration centers designated by the National Health Commission to conduct multidisciplinary team (MDT) treatment for colorectal cancer. The center is characterized by its laparoscopic low anterior resection for colorectal cancer with functional sphincter preservation and intersphincteric resection (ISR), and holds a leading position in minimally invasive colorectal surgery, precision treatment of advanced tumors, and surgical treatment of inflammatory bowel disease in China.

Historical Origins and Spiritual Inheritance:

The West China Colorectal Cancer Center is headed by Professor Zhou Zongguang, a Changjiang Scholar and recipient of the National Science Fund for Distinguished Young Scholars. Professor Zhou is the chief editor of the national "13th Five-Year Plan" textbook "Surgery" and pioneered laparoscopic TME (Transurethral Extraction) functional sphincter-preserving surgery for ultra-low rectal cancer in China. His achievements have been included in the guidelines of the European Association of Endoscopy (EAES) and the Japanese Society of Colorectal Cancer (JSCCR).

Core business operational efficiency:

The center has 94-96 beds (Jinjiang Campus), performs over 3,000 colorectal tumor surgeries annually, handles over 500 complex MDT consultations annually, and performs over 500 gastrointestinal emergency surgeries annually. Currently, it has 6 senior-level professionals, 6 associate senior-level professionals, 3 doctoral supervisors, and 11 master's supervisors. The Department of Anorectal and Pelvic Floor Surgery is led by Chief Physician Kang Yue, who has over 30 years of experience in gastrointestinal surgery and possesses profound expertise in pelvic floor and anal diseases, having established a minimally invasive diagnostic and treatment system for anorectal and pelvic floor surgery.

Discipline Positioning and Benchmarking:

It is one of the first five MDT (Multidisciplinary Team) demonstration bases in the country. The center has led or participated in drafting national guidelines and consensuses such as the "Chinese Expert Consensus on the Diagnosis and Treatment of Lateral Lymph Node Metastasis in Rectal Cancer (2019/2024 Edition)," "Chinese Guidelines for the Treatment of Colorectal Cancer," "Guidelines for Colorectal Cancer and Anal Canal Cancer of the Chinese Anti-Cancer Association," "Chinese Expert Consensus on Preventive Colostomy in Mid-to-Low Rectal Cancer Surgery (2022 Edition)," "Expert Consensus on the Standard Operating Procedures for 4K Laparoscopic Surgery in Colorectal Cancer (2020 Edition)," and "Expert Consensus on Surgical Treatment of Inflammatory Bowel Disease." As the first author and the first author's institution, he has won two national science and technology awards, four ministerial and provincial first-class science and technology awards, and one of the top 100 outstanding doctoral dissertations in the country.

The National Cardiovascular Clinical New Drug Trial (GCP) Base was approved as a "Sichuan Provincial Key Laboratory for Cardiac Structure and Function Research" in 2024. It has a Cardiovascular Disease Research Laboratory (open laboratory) focusing on three major directions: cardiovascular biomechanical mechanisms, precision medicine, and regenerative medicine. In the past five years, it has received 18 national-level projects (including 863 Program, National Science and Technology Support Program, National Natural Science Foundation of China, etc.) and 54 provincial and ministerial-level projects, published nearly 500 SCI papers, with the highest impact factor being 44.409, and led the development of one international guideline.

1. Historical Origins and Spiritual Inheritance

The Department of Cardiology at West China Hospital was founded in 1965 by Professor Luo Decheng. Its predecessor can be traced back to the establishment of the department in 1954. In 1960, the first cardiac catheterization room in Southwest China was built. In 1972, the Cardiovascular Professional Group was officially established, with Professor Lang Enpu as the first group leader. In 1986, it became an independent Department of Cardiology. Adhering to the principle of "striving for excellence and continuous innovation", the department started by establishing the first cardiac catheterization room in Southwest China and gradually developed into one of the birthplaces of cardiovascular interventional technology in China. It is one of the five hospitals in China that first carried out radiofrequency ablation, performed the first biventricular pacing treatment in China, and was one of the first hospitals in China to carry out transcatheter aortic valve replacement (TAVR). It is a national key clinical specialty, with a doctoral program and postdoctoral research station in cardiovascular medicine, a national GCP clinical trial base for new cardiovascular drugs, and conducts translational research on cardiovascular diseases based on the National Major Scientific and Technological Infrastructure for Translational Medicine. It is also one of the three major interventional technology training bases for coronary heart disease, arrhythmia and congenital heart disease of the National Health Commission, and one of the four major national training and assessment bases for cardiovascular specialists.

1. Core Business Operation Efficiency

The department has eight subspecialties: coronary artery disease, arrhythmia, valvular heart disease, heart failure, hypertension, pulmonary vascular disease, congenital heart disease, and cardiac intensive care. It has 247 beds (including 39 CCU beds), 10 subspecialty groups (valvular heart disease, coronary artery disease, hypertension, cardiac electrophysiology, pacing, congenital heart disease, cardiac intensive care, heart failure, pulmonary hypertension, and non-invasive electrocardiogram examination), and is equipped with 9 interventional catheterization rooms and hybrid operating rooms. It admits more than 16,000 inpatients annually and performs more than 30,000 interventional procedures annually. Critically ill and complex patients account for 92% of the cases, and the success rate of critical care resuscitation is 97%. The number of interventional treatments ranks first in Southwest China. The medical team includes 9 doctoral supervisors and 20 senior physicians; it also has five nationally certified centers: Chest Pain Center, Atrial Fibrillation Center, Heart Failure Center, Hypertension Center, and Cardiac Rehabilitation Center; it is the affiliated unit of the Sichuan Provincial Cardiovascular Disease Quality Control Center, and undertakes the work of cardiovascular disease quality control and technology promotion in Southwest China.

1. Discipline Positioning and Benchmarking

It is a National Key Clinical Specialty, a Key Discipline of Sichuan Province, the Sichuan Provincial Cardiovascular Disease Quality Control Center, and the Western Region's Center for the Diagnosis and Treatment of Complex and Critical Cardiovascular Diseases. It has consistently ranked 7th in the Fudan University Specialty Reputation Ranking, 5th in the China Hospital Science and Technology Evaluation Specialty Ranking, and 22nd globally in the 2023 Global Hospital Cardiovascular Academic Influence Ranking. Transcatheter aortic valve intervention (TAVR/TAVI) is among the world's leading institutions. Its expertise in complex coronary interventions, three-dimensional mapping ablation for arrhythmias, refractory hypertension, and device-assisted treatment for severe heart failure has reached top domestic and advanced international levels. Benchmarking against top European and American heart centers, it is a major global clinical research center for TAVR and one of the world's largest sample centers for bicuspid aortic valve intervention cases. It serves as a referral center for complex and critical cardiovascular diseases in western China, handling referrals of high-risk valvular heart disease, chronic total occlusion (CTO), and complex arrhythmias from across the country.

This national key discipline and key clinical specialty is a national standardized training base for cardiovascular surgeons, a national TAVI surgery teaching base, and a training center for minimally invasive valve intervention techniques. It is integrated into the national cardiovascular disease research platform system and has established three major disease databases—aortic disease, congenital heart disease, and heart transplantation—along with supporting translational laboratories. In the past five years, it has published 229 articles, including 17 high-impact articles in top-tier journals, consistently ranking among the top 5 in the country in terms of both the number of publications and the STEMI research score. It has been granted 26 national-level research projects and 133 provincial and ministerial-level and other research projects, with funding exceeding 50 million yuan.

1. Historical Origins and Spiritual Inheritance

Founded by renowned cardiovascular surgeons Professors Yang Zhenhua and Yang Jingguo, who returned to China in the 1950s, West China Cardiovascular Surgery Center is one of the earliest established cardiac and vascular surgery centers in the country. It performed its first cardiac surgery in 1957 and pioneered open-heart surgery with extracorporeal circulation in 1962. In 1994, it founded the *Chinese Journal of Cardiovascular Surgery*. The center upholds the rigorous, meticulous, and collaborative spirit of West China Cardiovascular Surgery, emphasizing critical care and multidisciplinary teamwork. Its core spirit is embodied in the motto "Pioneering Spirit, Leading with Minimally Invasive Techniques"—from extracorporeal circulation to transapical transluminal aspiration (TAVI), technological innovation has consistently driven the center's development.

1. Core Business Efficiency

The hospital has three campuses: the main campus, Shangjin Campus, and Tianfu Campus, with a total of approximately 220 beds. It sees over 70,000 outpatients annually and performs approximately 6,000 cardiovascular surgeries annually, consistently ranking among the top in the country. The team of physicians consists of 39 people, including 5 doctoral supervisors and 6 master's supervisors. The subspecialties are comprehensively divided into seven areas: great vessel surgery, valvular surgery, coronary surgery, congenital heart disease, heart transplantation, minimally invasive cardiac surgery, and pulmonary embolism surgery. It has a high proportion of surgeries for complex aortic dissection, severe valvular disease, and end-stage heart failure, with perioperative mortality rates better than international baseline levels, making it a leading center for the diagnosis and treatment of complex and severe cardiovascular diseases in Southwest China.

1. Discipline positioning is aligned with the national standards.

It is a National Key Discipline of the Ministry of Education (2007), a National Key Clinical Specialty Construction Project (2011), a Training Base for Cardiovascular Surgeons of the Ministry of Health (2006), a National TAVI Surgery Teaching Base (2017), and a Minimally Invasive Valve Interventional Technology Training Center (2021). It consistently ranks among the top tier of cardiac surgery in China according to Fudan University's Specialty Reputation Ranking and the China Hospital Science and Technology Evaluation Standards (STEM). It leads the Western Cardiovascular Surgery Alliance and undertakes a large number of national-level clinical research projects. Benchmarking globally: We have long-term academic collaborations with the Cleveland Clinic in the United States and the Toronto Children's Heart Center in Canada. We have completed the world's first transapical TAVR treatment for aortic regurgitation and Asia's first total thoracoscopic radiofrequency ablation. Many of our procedures have been cited in international guidelines.

It is a national key clinical specialty, one of the first doctoral and master's degree granting units authorized by the State Council, and the World Federation of Neurosurgical Societies (WFNS) China Continuing Education Center. It is affiliated with the West China Institute of Neurological Diseases and is included in the National Regional Medical Center for Neurological Diseases research platform system. It is also one of the first three national neurosurgery physician training bases designated by the National Health Commission. It houses the West China Hospital Institute of Neurological Diseases and the Microsurgical Neurosurgery Training Center (established in 2007). In the past three years, he has undertaken more than 100 national, ministerial and provincial research projects and published more than 450 SCI papers, including top international journals such as The Lancet, Science Advances, Cancer Discovery and Nature Communications. He has won more than ten awards, including the first and second prizes of the Chinese Medical Science and Technology Award and the Ministry of Education Science and Technology Progress Award.

1. Historical Origins and Spiritual Inheritance

The Department of Neurosurgery at West China Hospital was founded in the 1950s (1953) by senior experts such as Qiu Tiguang, Huang Kewei, Wu Heguang, and Gao Lida. It is one of the earliest specialized neurosurgery wards in my country. As one of the first three national training bases for neurosurgeons designated by the Ministry of Health, the department has accumulated over sixty years of experience and has developed the spirit of "unity, dedication, rigor, and perseverance." Inheriting the spirit of "overcoming difficulties, precision and minimally invasive techniques, and multidisciplinary collaboration," the department was the first in China to complete subspecialty subdivision in 2005, establishing 10 standardized subspecialty groups to achieve specialized treatment for specific diseases.

1. Core Business Efficiency

Currently, it has campuses including West China Hospital (main campus), Jinjiang, Shangjin, and Tianfu, with 440 beds (including 70 NICU beds); it sees over 200,000 outpatients annually, performs over 14,000 craniotomies, over 2,600 endovascular interventional surgeries, and over 6,700 neurointerventional and stereotactic radiosurgeries annually. Level IV complex surgeries account for more than 70% of its procedures, making it the largest neurosurgical critical care center in Southwest China.

1. Discipline Positioning

Benchmarking against national standards: It was among the first batch of National Key Clinical Specialties designated by the National Health Commission, and among the first batch of institutions authorized by the State Council to grant doctoral (1986) and master's (1981) degrees. It is also the WFNS World Neurosurgical Specialist Training Center (the second in China). Since 2011, it has consistently ranked third in neurosurgery nationwide in the Fudan University's ranking of Chinese hospital specialty reputations, and its STEM (Science, Technology, Engineering, and Mathematics) ranking among the top in China. It spearheaded the establishment of the West China Neurosurgical Discipline Alliance, covering more than 500 regional hospitals. Benchmarking against global standards: The core members of the department are members of WFNS and the American Association of Neurosurgeons (AANS), and have participated in the writing of multiple domestic guidelines and international consensus on intracranial aneurysms, craniopharyngiomas, and gliomas. They have reached international advanced levels in the fields of complex skull base surgery, cerebrovascular complex surgery, and functional neurosurgery.

A national key clinical specialty and a national standardized training base for nephrologists; the West China Nephrology Institute, a platform for the diagnosis, treatment, and translational research of complex and severe nephrological cases in western China. Based at the West China Nephrology Institute (approved and established in 2014, with Professor Fu Ping as director), the institute focuses on the construction and basic research of clinical sample banks for diabetic nephropathy, IgA nephropathy, and ANCA vasculitis-related nephropathy. In the six years since its establishment, the institute has published over 50 SCI papers and received nearly 20 grants, including sub-projects of the National Key Research and Development Program and the National Natural Science Foundation of China (NSFC) Youth Fund. Professor Fu Ping's team has accumulated approximately 10 million yuan in research funding, published nearly 400 papers (more than 130 of which are SCI-indexed), and edited the monograph "Continuous Renal Replacement Therapy" published by People's Medical Publishing House.

1. Historical Origins and Spiritual Inheritance

Hemodialysis was introduced in 1978, a nephrology specialty group was established in 1980, and it officially became an independent department in 1986. Founded by Professor Xu Guozhang, it has developed a sustainable academic team led by Professors Yu Tinglong, Liu Xianrong, Tao Ye, Huang Songmin (former Standing Committee member of the Chinese Nephrology Society), and Fu Ping (Standing Committee member of the Nephrology Branch of the Chinese Medical Association). Its core philosophy is "integrated care and comprehensive management"—from acute treatment to chronic follow-up, with the core mission of slowing renal function deterioration and improving patients' quality of life. Inheriting the spirit of West China Nephrology Hospital—precise renal biopsy, treatment of severe renal injury, and integrated management of long-term chronic diseases—it has built an integrated renal disease diagnosis and treatment system encompassing "clinical-pathological-blood purification-basal translation," and is one of the earliest units in China to systematically carry out renal pathology and blood purification.

1. Core Business Operation Efficiency

The largest kidney disease diagnosis and treatment center in western China, specializing in complex and critical cases, currently has 32 doctors, including 5 doctoral supervisors and 13 master's supervisors. The peritoneal dialysis center maintains follow-up for over 500 patients on peritoneal dialysis, ranking first in central and western my country and fourth nationwide. In early 2011, it pioneered laparoscopic peritoneal dialysis catheter placement in China, a leading technique domestically. The hospital performs nearly 2,000 renal biopsies and over 2,000 vascular access interventional surgeries annually, with 100,000 blood purification treatments per year. CRRT treatment lasts 8,000 hours per month, and the hospital provides renal replacement therapy for critically ill patients in the ICU. It offers outpatient clinics for chronic kidney disease follow-up, vascular access, and lupus nephritis. The hospital has established a comprehensive CKD follow-up management system, and was among the first in China to establish a three-in-one (doctor, nurse, and nutritionist) chronic disease follow-up model. It undertakes multiple national key research and development projects and National Natural Science Foundation of China projects, and leads multi-center clinical research on kidney disease nationwide.

1. Discipline Positioning and National/Global Benchmarking

It is a key clinical specialty of the Ministry of Health, a dual key nephrology specialty of the Sichuan Provincial Department of Education and the Department of Health, a national training base for nephrology resident physicians of the Ministry of Health, and a training base for blood purification centers of county-level hospitals of the Ministry of Health. It is the largest center for the diagnosis and treatment of complex, critical and severe kidney diseases in western my country. It ranks among the top in the national Fudan University specialty reputation list and ranks third in the national hospital science and technology evaluation for nephrology. It is benchmarked against the Johns Hopkins Nephrology Center and the Mayo Clinic Nephrology Center. Core strengths: pathological diagnosis of complex kidney diseases, CRRT treatment system for severe acute kidney injury, interventional procedures for complex dialysis vascular access, and real-world field studies of chronic kidney disease; leading/co-authoring multiple domestic guidelines and expert consensus on acute kidney injury, blood purification, and lupus nephritis; serving as a leading academic center for kidney diseases in western China.

12737

The Department of Urology, West China Hospital, Sichuan University (established in 2014) and the Sichuan Provincial Clinical Medical Research Center for Kidney and Urinary System Diseases (designated in 2023) are located here. The department has six specialized laminar flow operating rooms and is equipped with one fourth-generation DaVinci surgical robot (Xi system). Its subspecialties cover eight areas: urological oncology, repair and reconstruction, prostate diseases, andrology, transplantation and dialysis, urinary incontinence, stones, and minimally invasive surgery. It is one of the most comprehensive and competitive disciplines in China in terms of subspecialties in urology.

1. Historical Origins and Spiritual Inheritance

West China Hospital's Department of Urology is one of the earliest established urology departments in my country. For a long time, it has served as a medical, research, and teaching center for urological diseases, minimally invasive urology, and kidney transplantation, consistently ranking among the top in the country in terms of overall academic level. The core spirit of the department is condensed into "minimally invasive leadership and equal emphasis on repair and reconstruction"—from traditional open surgery to robotic remote surgery, from routine tumor resection to complex urinary tract reconstruction, it consistently expands the boundaries of urological treatment through technological innovation. Inheriting the medical spirit of "high moral character, professional excellence, pragmatism and innovation" of West China Hospital, it was approved to establish a master's degree program in 1978 and a doctoral degree program in 1984, and established a postdoctoral research station. In 2012, it was selected as a national key clinical specialty. In 2014, the West China Institute of Urology was established. In 2023, it was approved as a national/provincial-level scientific research platform of Sichuan Provincial Clinical Medical Research Center for Kidney and Urinary System Diseases. It integrates medical treatment, scientific research, teaching and translation, and is a core base for the diagnosis and treatment of difficult and critical urological diseases in China.

1. Core Business Operation Efficiency

The department comprises eight subspecialties: urological oncology, urinary tract repair and reconstruction, urinary calculi, prostate/andrology, female urology and urinary incontinence, and kidney transplantation. Its three major areas of urinary tract repair and reconstruction, complex urinary calculi, and urological oncology MDT (Multidisciplinary Team) have reached international advanced levels. It has 269 beds, with over 190,000 outpatient visits and over 10,000 inpatient discharges annually, performing approximately 21,000 surgeries per year. It is equipped with the da Vinci Xi IV surgical robot and advanced endoscopic systems. It boasts Asia's first ACS-accredited urology training center and a SIU (Surgical Society of International Urology) accreditation center. It is an accredited training center and the Royal College of Surgeons of Edinburgh International Specialist Training Center. It is the only discipline in China that simultaneously has vice chairpersons/vice presidents of the Urology Branch of the Chinese Medical Association and the Urology Branch of the Chinese Medical Doctor Association. It has a complete team of specialist talents, with 18 senior professors and 14 doctoral supervisors.

1. Discipline Positioning and Benchmarking

It is a National Key Clinical Specialty (approved in 2012), a unit authorized to grant Master's/Doctoral degrees in Urology, and a postdoctoral research station. It is also the Southwest Minimally Invasive Urology Training Center of the Chinese Medical Association's Urology Branch. Together with its Clinical Skills Training Center, it became the first educational institution in Asia to be accredited by the American College of Surgeons (ACS). It boasts a top-tier urology team nationwide, ranking first in China's hospital science and technology rankings for four consecutive years. In the latest Fudan University ranking of China's Best Specialties, it ranks third in reputation, second overall, and first in research nationwide. As a national referral center for complex urological diseases, it leads the country in the number of cases treated, including complex urethral stricture, staghorn calculi, advanced urogenital tumors, and complex kidney transplants. It benchmarks against top urology centers in Europe and the United States and keeps pace with international frontiers in minimally invasive robotic surgery, tissue-engineered urinary tract reconstruction, and precision translational medicine for urological tumors.

7412737

A national key specialty in nuclear medicine, and a benchmark center for integrated radioligand diagnosis and treatment of prostate cancer in western China.

1. Historical Origins and Spiritual Inheritance

Founded in 1958, the Department of Nuclear Medicine at West China Hospital is one of the earliest nuclear medicine specialties in China. It was approved to offer master's programs in 1978 and doctoral programs in 1993, and is a national key discipline and a national key clinical specialty designated by the Ministry of Education. Through four generations of academic inheritance, upholding the spirit of high moral character, professional excellence, and innovation, the department initially focused on radionuclide therapy for thyroid diseases. Since 2018, it has been deploying PSMA molecular imaging, and in 2023, it initiated the global multicenter Phase III clinical trial of ¹⁷⁷Lu-PSMA-617, becoming one of the first departments in western China to conduct PSMA trials. The center for radioligand therapy (RLT) has established an integrated system for the diagnosis and treatment of tumor radionuclide tumors, and undertakes the construction of the Western Nuclear Medicine Specialty Alliance, standardized nuclear medicine training, and GCP clinical trials of new radiopharmaceuticals. In the field of radionuclide therapy for prostate cancer, West China Hospital, relying on the urological oncology MDT team (established in 2013, one of the four major demonstration bases for urological oncology MDT in China), has achieved deep collaboration between nuclear medicine and urology.

1. Core Business Operation Efficiency

The department is equipped with a cyclotron accelerator, 4 SPECT/CT scanners, 4 PET/CT scanners, and PET/MR scanners; it performs over 40,000 SPECT/CT examinations annually (ranking first in the country), and nearly 20,000 PET/CT and PET/MR examinations annually. The radionuclide therapy ward treats 1,200 thyroid cancer patients annually. It has its own independent radionuclide therapy ward. In the prostate cancer field, it performs ⁶⁸Ga-PSMA PET/CT molecular imaging staging and lesion detection; its multidisciplinary team (MDT) collaborates with urology, oncology, and radiotherapy to evaluate candidate patients; it accepts referrals of PSMA-positive metastatic prostate cancer from across the country; and its urological oncology MDT has served 1,582 patients with complex and severe cases in the past 5 years, with an average annual growth rate of 22.5%. Undertake the global multicenter clinical trial of Lu-PSMA; conduct individualized internal radionuclide irradiation dose calculation for tumors, dynamic evaluation of efficacy, and full-process monitoring and follow-up of adverse reactions; lead the promotion of the prostate cancer special project of the Western Nuclear Medicine Specialty Alliance.

1. Discipline Positioning

West China Hospital is one of the earliest centers in China to initiate clinical research on 177Lu-PSMA RLT, with Professor Dong Qiang from the Department of Urology and Professor Huang Rui from the Department of Nuclear Medicine jointly undertaking the PSMAddition trial. The core differentiated advantage lies in the integrated closed-loop diagnosis and treatment: PSMA PET/CT is used for patient screening and staging, 177Lu-PSMA-617 is used for targeted therapy, and SPECT/CT is used for post-treatment dosage verification and efficacy evaluation.

A national key specialty in nuclear medicine, and a benchmark center for integrated radioligand therapy for prostate cancer in western China. Its focus is on providing comprehensive multidisciplinary team (MDT) care for advanced prostate cancer, combining PSMA molecular imaging with ¹⁷⁷Lu-PSMA targeted internal radiation therapy, integrating surgery, pharmacology, and radiotherapy. It conducts clinical translation of radioligand therapy, clinical trials of new radiopharmaceuticals, and precise staging using PSMA-targeted molecular imaging, filling the gap in radionuclide-targeted therapy for advanced prostate cancer in western China.

1. Core Advantages + National/Global Benchmarking

- National Benchmarking: One of the earliest research centers in China to launch a global Phase III clinical trial of ¹⁷⁷Lu-PSMA; ⁶⁸Ga-PSMA PET/CT and ¹⁷⁷Lu-PSMA integrated diagnosis and treatment system are among the top in China; benchmarking against Shanghai Renji and Fudan University's Nuclear Medicine Oncology Center; Differentiated Advantages: Relying on West China Hospital's strong urological oncology MDT system, it excels in the comprehensive evaluation of complex, multi-metastatic advanced prostate cancer; Weaknesses: The number of accumulated clinical cases in China is less than that of the pioneering center in the east, and the transformation of domestically produced PSMA-targeted radiopharmaceuticals is still underway.

- Global benchmarking: ¹⁷⁷Lu-PSMA treatment protocols, patient screening, and organ dosage assessment systems are benchmarked against Munich, Germany, and the Peter Mac Nuclear Medicine Centre, Australia; adherence to EANM and SNMMI radioligand diagnostic and treatment guidelines; weaknesses: clinical translation of α-nucleoside (²²⁵Ac-PSMA) started later than top centers in Europe and the United States, and independent research and development of novel PSMA ligands is relatively weak.

- Core Advantages: Closed-loop integrated MDT for PSMA diagnosis and treatment; precise localization using PET/MR+PSMA multimodal imaging; personalized organ absorption dosage estimation; multicenter clinical research platform for advanced prostate cancer in western China.

National/Global Benchmarks: The overall survival of metastatic prostate cancer patients treated by the West China Urology Oncology MDT reached 70.3 months, far exceeding the international standard; the overall survival of mCRPC patients treated by the MDT was extended by about 12 months.

The Department of Respiratory and Critical Care Medicine at West China Hospital of Sichuan University is one of the birthplaces of respiratory medicine in western China. It was among the first batch of national key disciplines designated by the Ministry of Education (2002), the first batch of national key clinical specialties designated by the Ministry of Health (ranked third nationally in 2011), and one of the first ten national demonstration units for standardized PCCM (Potentially Transmitted Chronic Disease) specialty construction. For many consecutive years, the department has ranked fourth to fifth in the Fudan University ranking of best hospital specialties in China, and for many consecutive years, respiratory medicine has ranked second nationally in the ranking of scientific and technological influence of Chinese hospitals. It is home to the National Key Laboratory of Respiratory and Comorbidities and the Institute of Respiratory Health, and is positioned as the core center for the diagnosis and treatment of complex and critical respiratory diseases in western China and the birthplace of respiratory therapy in China.

Historical Origins and Spiritual Inheritance:

The history of West China Hospital's Department of Respiratory Medicine can be traced back to the Department of Internal Medicine of Chengdu Renji Hospital, founded in 1892, and the Chengdu Pulmonary Sanatorium, founded in 1937. In 1953, these were merged into the Department of Internal Medicine of the Affiliated Hospital of Sichuan Medical College. In 1975, the Department of Respiratory Medicine was established, and in 1984, it was formally established as the Department of Respiratory Medicine. In 2012, it was renamed the Department of Respiratory and Critical Care Medicine. Over its more than 100-year history, it has produced many renowned respiratory masters in China, such as Luo Guangbi, Chen Wenbin, Wang Zengli, Lin Zhenxun, Yin Daikui, and Feng Yulin. In recent years, Li Weimin, Wen Fuqiang, Liang Zongan, and Liu Chuntao have become leading figures in their respective fields in China.

Core business operational efficiency:

The department comprises six medical and nursing units: a respiratory ward, a general respiratory ward, a tuberculosis ward, a respiratory ICU, a Jinjiang respiratory ward, and a Wenjiang lung cancer center ward, totaling 292 beds. This makes it one of the respiratory and critical care medicine departments with the largest number of beds in the country. Currently, there are nearly 300 staff members, including 24 professors/chief physicians, 9 associate professors/associate chief physicians, and 11 doctoral supervisors. 90% of the doctors hold doctoral or master's degrees. The department treats an average of over 120,000 outpatients and over 10,000 inpatients annually.

Discipline Positioning and Benchmarking:

It is among the first batch of national key disciplines designated by the Ministry of Education (2002), the first batch of national key clinical specialties designated by the Ministry of Health (2011), the first batch of national standardized PCCM construction demonstration units (2018), and a national training base for respiratory and critical care medicine (2017). Professor Li Weimin serves as the vice chairman of the Chinese Medical Association's Respiratory Diseases Branch and the deputy leader of the Lung Cancer Group; Professor Wen Fuqiang serves as a member of the Clinical Committee of the American Thoracic Society and the deputy leader of the COPD Group of the Chinese Medical Association's Respiratory Diseases Branch; Professor Liang Zongan serves as a member of the Chinese Medical Association's Respiratory Diseases Branch and the leader of the Respiratory Therapy Group; Professor Liu Chuntao is an academic and technical leader in Sichuan Province and a recipient of the "Outstanding Respiratory Physician in China" award.

This is a national key clinical specialty and a branch center of the National Clinical Research Center for Infectious Diseases. The Institute of Infectious Diseases is affiliated with the National Key Laboratory of Biological Therapy; a national GCP clinical trial base for anti-infective drugs; and a national standardized training base for infectious diseases designated by the National Health Commission. It is also a national base for clinical research on anti-infective drugs (established in 1983) and a national training base for physicians specializing in bacterial and fungal infections under the "Peiyuan Project" (the only one in western China). It relies on the Infectious Diseases Research Laboratory of the National Key Laboratory of Biological Therapy (a center affiliated with the Institute of Infectious Diseases). Currently, it has 136 professional and technical personnel, including 12 professors, 14 associate professors, 5 doctoral supervisors, and 16 master's supervisors, among whom are recipients of the Ministry of Education's Yangtze River Scholar Award, the National Outstanding Youth Science Fund, and the National Excellent Youth Science Fund.

1. Historical Origins and Spiritual Inheritance

The discipline originated from the Department of Infectious Diseases, Department of Internal Medicine, West China Union University School of Medicine in 1937 (headed by Professor Cao Zhongliang), and was formally established as a department in 1953 (headed by Professor Huang Anhua). The core spirit of the discipline is condensed into "high moral character and professional excellence, seeking truth and innovation," and it follows the school motto of "people-oriented, respecting scholarship, and pursuing excellence." It was among the first in China to be approved for master's and doctoral programs in infectious diseases, as well as a postdoctoral research station.

1. Core Business Operation Efficiency

It comprises six subspecialties: viral hepatitis, artificial liver, bacterial and fungal infections, HIV and opportunistic infections, fever of unknown origin, and tuberculosis; the Jinjiang campus has 130 beds (including an infectious disease ICU), and the Jincheng campus has 50 beds; it sees over 300,000 outpatients annually and discharges approximately 4,000 patients annually; it performs over 1,700 artificial liver treatments annually; the team includes 5 doctoral supervisors, 16 master's supervisors, and 12 senior professional title holders; it possesses a P3 biosafety laboratory and a metagenomic pathogen sequencing platform; it undertakes emergency treatment of sudden infectious diseases in Southwest China and remote consultations for difficult infections, and receives visiting physicians from across the country every year.

1. Discipline Positioning and Benchmarking

It is a National Key Clinical Specialty (approved in 2013), a branch of the National Clinical Research Center for Infectious Diseases, and the Sichuan Provincial Center for Quality Control of Infectious Diseases. It ranks 6th nationally in the Fudan University Specialty Reputation Ranking and 2nd nationally in the STEM (Science, Technology, Engineering, and Mathematics) Hospital Evaluation Index. Its three major areas—artificial liver support system for severe liver failure, precision diagnosis and treatment of multidrug-resistant bacteria/invasive fungal infections, and identification of pathogens causing fever of unknown origin—have reached international advanced levels. It benchmarks itself against the Johns Hopkins Infectious Diseases Center in the United States and the Munich Infectious Diseases Center in Germany. It is a national core referral center for complex and severe infections, complicated liver failure, and opportunistic infections in immunocompromised hosts. It leads multiple national-level major infectious disease projects and participates in the formulation of domestic guidelines for the management of infectious diseases, liver diseases, and antimicrobial drugs.

The department is a drug clinical trial base approved by the State Food and Drug Administration. It has undertaken more than 100 research projects, including National Key Research and Development Programs and National Natural Science Foundation of China projects, with a total funding of 30 million yuan, and has published more than 200 scientific papers. It has established several specialized databases for diseases such as inflammatory myopathy, rheumatoid arthritis, immune-related adverse pregnancy, and systemic lupus erythematosus, providing a complete data platform for clinical cohort studies.

1. Historical Origins and Spiritual Inheritance

The Department of Rheumatology and Immunology at West China Hospital is the youngest of the eight subspecialties in internal medicine. After more than 30 years of vigorous development, it has grown into a national key clinical specialty (approved in 2013) and a provincial key discipline. It is also the earliest institution in western my country authorized to grant doctoral and master's degrees in rheumatology. Founded by Professors Lin Maoxian, Wu Changbi, and Huang Yumei, the department opened a rheumatology outpatient clinic in 1987 and formally established a rheumatology and immunology ward in 1995. Adhering to the disciplinary philosophy of "driving research with clinical problems and using translational research to support clinical practice," the department started from a blank in the diagnosis and treatment of rheumatic and immunological diseases in Southwest China and has gradually built a regional center covering the entire spectrum of diseases, with the ability to treat complex and critical cases. Inheriting the medical spirit of "high moral character, professional excellence, pragmatism and innovation" of West China Medical Center, it is the first institution in western China authorized to grant doctoral and master's degrees in rheumatology; relying on the National Major Scientific and Technological Infrastructure for Translational Medicine and the National Key Laboratory for Biological Therapy to carry out research on immune-inflammatory transformation, and a national GCP base for drug clinical trials; it is one of the earliest centers in China to establish biological targeted therapy for rheumatology.

1. Core Business Operation Efficiency

The department has four subspecialties: inflammatory myopathy, systemic lupus erythematosus, inflammatory arthritis, and stem cell immunotherapy. As a leading center for the diagnosis and treatment of complex and critical rheumatic and immunological diseases in Southwest China, the department sees over 220,000 outpatients annually, has 84 specialized beds, and discharges over 3,300 patients annually, with over 50% being complex or critically ill patients. More than 70% of the clinical physicians hold doctoral degrees, including 13 senior professionals, 8 doctoral supervisors, 10 master's supervisors, 1 National Outstanding Young Scientist, and 1 Overseas Outstanding Young Scientist. It also boasts a nationally leading rheumatology biological therapy center and an immunoadsorption/ The hospital has a plasma exchange therapy unit; it has established a large-scale disease registry and biobank for inflammatory myopathy, rheumatoid arthritis, and systemic lupus erythematosus; it undertakes the referral of patients with complex rheumatic and immunological diseases in Southwest China and the standardized training of specialist physicians, receiving more than 20 visiting physicians from across the country each year.

1. Discipline Positioning and Benchmarking

The hospital is among the top-tier rheumatology and immunology departments in China, ranking fifth or sixth in the Fudan University's ranking of Chinese hospital specialties for five consecutive years. Its STEM (Science, Technology, Engineering, and Mathematics) ranking has consistently placed it among the top five in China. It has achieved internationally advanced levels in four key areas: immune purification therapy for severe connective tissue diseases, inflammatory myopathy combined with interstitial lung disease, stem cell clinical transformation of refractory autoimmune diseases, and research on the immune mechanism of gout lenses. It benchmarks itself against the Karolinska Institute in Sweden and the Mayo Clinic Rheumatology Center in the United States, and conducts long-term international collaborative research. It serves as the final referral center for complex and critical rheumatic and immunological diseases in Southwest China, handling cases of severe lupus, rapidly progressive myopathy-related interstitial lung disease, refractory systemic sclerosis, and systemic vasculitis nationwide.

A national key clinical specialty and a key discipline in Sichuan Province, it was approved as the Sichuan Provincial Endocrine Medical Quality Control Center in 2018 and a national-level treatment center for complex and critical endocrine and metabolic diseases in western China. Its focus is on treating complex pituitary/adrenal diseases, refractory diabetes, diabetic foot, metabolic bone diseases, and rare endocrine diseases in Southwest China and nationwide. It serves as an integrated specialty platform encompassing clinical diagnosis and treatment, multidisciplinary team (MDT) consultations, clinical translation, guideline development, and talent training.

1. Historical Origins and Spiritual Inheritance

The Department of Endocrinology and Metabolism was established in the late 1950s, and the Endocrinology Specialty Group was formally established in 1962, making it one of the earliest endocrinology specialties established in medical colleges in China. Founded by pioneering figures in endocrinology such as Liang Yizhong, Deng Shangping, Zhang Cunhong, and Li Xiujun, it has developed over sixty years into a discipline that emphasizes both clinical and basic research, in-depth subspecialty cultivation, and multidisciplinary collaboration. It was among the first in China to establish master's and doctoral programs in endocrinology, as well as a postdoctoral research station. In 2023, the department was designated a national key clinical specialty and has consistently ranked among the top 5 in the STEM rankings nationwide. It inherits the spirit of "high moral character, professional excellence, pragmatism, and innovation" of West China Medical Center.

1. Core Business Operation Efficiency

The main campus and West China Tianfu Campus together have 93 beds; the annual outpatient volume is 130,000 to 180,000 visits, the annual inpatient admission is about 4,000, and the annual discharge is 2,300 to 3,700, covering patients from 30 provinces, municipalities and autonomous regions across the country; it has 9 subspecialties and has established a diabetic foot treatment center, a pituitary tumor MDT center, an adrenal disease treatment center, and a diabetes education center; it is also the Sichuan Provincial Endocrine Medical Quality Control Center and the Sichuan Provincial Clinical Medical Research Center for Diabetes and Metabolic Diseases; it undertakes a large number of Phase I-IV endocrine and metabolic drug GCP clinical trials, western endocrinologist training, and grassroots endocrinology quality control support; the annual referral volume of complex endocrine rare diseases and refractory metabolic diseases ranks first in western China.

1. Discipline Positioning

A national key clinical specialty and a national-level treatment center for complex and critical endocrine and metabolic diseases in western China; ranked 3rd-5th in China's hospital science and technology evaluation rankings for the past 5 years, and consistently ranked 6th nationally and 1st in western China in Fudan University's specialty reputation rankings. Its core strengths lie in three major areas: diabetic foot and peripheral vascular disease, metabolic bone disease, and pituitary-adrenal diseases, with its diabetic foot diagnosis and treatment being among the best in the country. Positioning: To address complex pituitary/adrenal diseases, refractory diabetes, diabetic foot, metabolic bone disease, and rare endocrine diseases in Southwest China and nationwide; a comprehensive specialty platform integrating clinical diagnosis and treatment, multidisciplinary team (MDT) consultations, clinical translation, guideline development, and talent training.

1. Core Advantages + National/Global Benchmarking

- National Benchmarking: Consistently ranked among the top 7 in the Fudan Specialty Reputation Ranking, and consistently ranked 3rd-5th in the STEM (Science, Technology, Engineering, and Mathematics) Endocrinology Department of China; Leading domestic expertise in four major areas: diabetic foot, pituitary diseases, primary aldosteronism subtyping and treatment, and metabolic bone diseases; Many technologies were pioneered or first implemented domestically; Led the compilation of multiple domestic endocrinology guidelines and expert consensus, and is one of the core consultation platforms for complex endocrine diseases in China.

- Global benchmarking: The autologous platelet-rich gel wound repair for diabetic foot and the multi-pathway adrenal vein blood sampling AVS technology solution are globally leading solutions; comparable to top endocrinology centers in Europe and the United States (Mayo Clinic, Joslin Diabetes Center); possesses unique advantages in the Chinese metabolic disease rankings and the database of rare endocrine diseases in western China; weaknesses: there is still a gap compared with top international centers in the original translation of basic mechanisms and the scale of independent research and development of novel metabolic target drugs.

- Core Advantages: Multi-Association Professional MDT Closed-Loop System; Western China's Largest Endocrine Hormone Testing Platform; China's Largest Real-World Sample of Diabetes, Obesity, and Adrenal Diseases; Diabetic Foot Comprehensive Foot Care Management System, a Domestic MDT Model Benchmark.

The National Clinical Research Center for Geriatric Diseases (a national science and technology innovation base for technological innovation and achievement transformation) is the only national-level clinical research platform for geriatric diseases in western China. It is a national key clinical specialty and the Sichuan Provincial Center for Quality Control of Geriatric Medical Care. The discipline is centered on a holistic, individualized, and multidisciplinary integrated geriatric medicine model, distinct from the traditional single-organ specialty treatment model. It has undertaken over 100 national projects, including the National 973 Program, the National 863 Program, and the National Natural Science Foundation of China, and has won over 10 science and technology awards at various levels. It has established large-scale clinical research stations, including the Western China Multi-Ethnic Group Frailty Station (7533 cases, involving 18 ethnic groups), the Centenarian Station (1875 cases), and the Community Sarcopenia Station (6376 cases).

1. Historical Origins and Spiritual Inheritance

Established in the 1980s, the department is one of the earliest geriatric medicine specialties in China; it was officially designated a geriatric medicine center in 2013; and in 2016, it was approved as a national clinical research center for geriatric diseases. After more than fifty years of development, it has refined its mission to "focus on the entire life cycle and health process of the elderly," striving to shift from a "disease-centered" approach to one centered on "health and quality of life." Inheriting the West China Hospital's geriatric medicine philosophy of holistic care, functional priority, comprehensive management of chronic diseases and comorbidities, and consideration for quality of life, it abandons the single-organ treatment approach, focusing on the overall functional maintenance of the elderly, and pioneered the establishment of a comprehensive geriatric assessment (CGA) system in China.

1. Core Business Operation Efficiency

With 4 wards and 300 beds, it treats over 20,000 elderly patients annually, making it the largest specialized geriatric disease center for the diagnosis and treatment of complex and critical illnesses in Sichuan Province and Southwest China. It offers outpatient services for comprehensive geriatric assessment, chronic geriatric diseases, frailty/sarcopenia, and palliative care; and has established acute care wards, functional enhancement wards, and palliative care wards for the elderly. We routinely conduct comprehensive geriatric assessments, polypharmacy remediation, and perioperative geriatric risk assessments; we undertake multidisciplinary team (MDT) consultations for geriatric patients with multiple coexisting diseases, geriatric syndromes, and critically ill elderly patients; we are responsible for the training of geriatric medical professionals nationwide and lead the construction of a collaborative network for geriatric medicine in western China; we have undertaken more than 100 research projects, including National Key Research and Development Programs, 973 Program, and National Natural Science Foundation of China projects.

1. Discipline Positioning and National/Global Benchmarking

It is the National Clinical Research Center for Geriatric Diseases (approved in 2016, the only one in western China), a key specialty of geriatric medicine designated by the National Health Commission, the Sichuan Provincial Center for Quality Control of Geriatric Medical Care, and the only research collaboration unit in China of the International Association of Gerontology and Geriatrics (IAGG). It has consistently ranked among the top three in the Fudan University's ranking of Chinese hospital specialty reputations for many years, and tied for second place nationwide in the 2023 comprehensive ranking. It benchmarks itself against Johns Hopkins University Geriatrics Center in the United States and Cambridge Geriatrics Centre in the United Kingdom. Core strengths: Evidence-based intervention system for frailty/sarcopenia and delirium in the elderly; perioperative risk management for the elderly; management of multiple coexisting diseases and multiple medications; palliative care; leading and participating in the compilation of multiple domestic geriatric medicine guidelines and international sarcopenia guidelines; possessing a leading domestic long-term follow-up team for the elderly.

Relying on the Key Laboratory of Transplantation Engineering and Transplantation Immunology of the Ministry of Health and the Hepatobiliary and Pancreatic Research Laboratory, it has won numerous awards, including the Second Prize of the National Science and Technology Progress Award and the First Prize of the Sichuan Provincial Science and Technology Progress Award. Its distinctive and advantageous research directions include: living donor liver transplantation, autologous liver transplantation for hepatic echinococcosis (internationally pioneering cadaveric liver + living donor synthetic liver transplantation); integrated traditional Chinese and Western medicine treatment of acute severe pancreatitis (pioneering the SAP integrated diagnosis and treatment model, reaching international advanced levels); and regional micro-metastasis and minimally invasive sphincter-preserving surgery for rectal cancer (establishing China's first standardized minimally invasive surgical standard for colorectal tumors). 1. Historical Origins and Spiritual Inheritance

The Department of General Surgery at West China Hospital originated from the Department of Surgery at West China Union University. It is one of the earliest established surgical specialties in my country, with its origins dating back to the 1950s. In the 1950s, a subspecialty system of hepatobiliary and pancreatic, gastrointestinal, pancreatic, and abdominal wall hernia was gradually formed. Professor Wu Yantao began animal experiments on liver transplantation in 1977, and Professor Yan Linan led the implementation of clinical liver transplantation in 1999. In 2002, the first adult living donor liver transplant in China was completed, which established the academic status of West China General Surgery in the country. It was approved as a national key discipline by the Ministry of Education and selected as a national key clinical specialty in 2012. It has a doctoral program and postdoctoral research station in surgery. It is an international surgical certification training base of the Royal College of Surgeons of Edinburgh, UK. It is one of the earliest surgical centers in China to establish an integrated treatment system for severe acute pancreatitis, a living donor liver transplantation system, and a standardized system for laparoscopic gastrointestinal tumors. The core spirit is condensed into "daring to be the first and venturing into forbidden territory"—from the first adult living donor liver transplant in China to the world's first eRPS procedure, it has always pushed the limits of surgery through technological innovation. Relying on the national major scientific and technological infrastructure for translational medicine and the national key laboratory for biological therapy, it has built an integrated research chain of clinical-basic-translational studies, and has won the second prize of the National Science and Technology Progress Award. It inherits the century-old surgical heritage of West China Hospital, characterized by "high moral character, professional expertise, pragmatism, and innovation."

1. Core Business Operation Efficiency

The Department of General Surgery is the largest surgical department at West China Hospital, encompassing multiple subspecialties including hepatobiliary surgery, biliary tract surgery, pancreatic surgery, gastrointestinal surgery, thyroid surgery, breast surgery, and vascular surgery. It has ample bed capacity, handles over 180,000 outpatient visits annually, and performs over 22,000 surgical procedures annually, with a high proportion of complex level IV surgeries. It is equipped with the da Vinci Xi surgical robot, a high-definition 4K laparoscopic system, and a percutaneous transhepatic cholangioscopy (PTCS) system. Its faculty includes 16 doctoral supervisors and 22 senior professionals. It treats a large number of cases referred from across the country involving complex hepatobiliary and pancreatic tumors, advanced gastrointestinal tumors, severe pancreatitis, complex hernias, and giant hepatic echinococcosis, with a high proportion of complex and critical cases.

1. Discipline Positioning and Benchmarking

It is a key discipline of the Ministry of Education (approved in 2002) and a key clinical specialty of the National Health Commission (approved in 2012), and has been included in the national "211 Project" key discipline construction project. In the Fudan University version of the China Hospital Specialty Reputation Ranking, the Department of General Surgery ranks among the top five in the country and among the top three in general hospitals, and has consistently ranked first in Southwest China. It is among the top-tier general surgery teams in China, consistently ranking among the top in the Fudan University Specialty Reputation Ranking and the China Hospital Science and Technology Evaluation Standards (STEM). Its four major areas of expertise—living donor liver transplantation, comprehensive treatment of severe acute pancreatitis (SAP), sphincter-preserving surgery for ultra-low rectal cancer, and minimally invasive treatment of complex hepatobiliary stones—have reached international advanced levels. Benchmarking against top general surgery centers in Europe and America, it is at the forefront of international research in robotic hepatobiliary and gastrointestinal surgery, perioperative precision treatment of tumors, accelerated recovery after surgery (ERAS), and organ transplantation translational research. It serves as a referral center for complex and critical general surgery cases in western China and a national demonstration base for standardized surgical procedures.

The Breast Disease Center of West China Hospital, Sichuan University, is a key discipline of the Ministry of Education and a key specialty of the National Health and Family Planning Commission. It is the largest breast disease diagnosis and treatment center in Southwest China. The center's core concept is the "West China Model" for comprehensive breast cancer management. Its internationally leading technological breakthrough is the reverse-sequence NSM-DTI (non-liposuction reverse endoscopic breast reconstruction via axillary single-port technique). In 2024, the center performed nearly 9,000 breast surgeries, including 3,581 breast cancer surgeries. Endoscopic surgeries accounted for 39.9%, and reconstructive surgeries accounted for 22.5%. It ranked third nationwide in the 2016 Fudan University Ranking of Best Specialty Reputation of Chinese Hospitals and third nationwide in the 2018 Ranking of Scientific and Technological Value of Chinese Hospitals.

Historical Origins and Spiritual Inheritance:

The West China Breast Surgery Department was established in the late 1970s and early 1980s. In 1979, with the approval of the hospital and the leadership of the Department of General Surgery, the Breast Surgery Specialty Group was formally established, founded by Professors Chen Peizhen, Yang Huazhang, and Yang Jinqiao. In April 2008, the Department of Breast Internal Medicine and Surgery was separated into Thyroid and Breast Surgery. In March 2015, the Breast Surgery Specialty Center was established. On June 1, 2017, the Breast Surgery Ward was established. On July 1, 2022, the West China Breast Disease Center was formally established.

Core business operational efficiency:

The center sees over 150,000 outpatients annually and performs nearly 8,000-9,000 surgeries per year, including 2,000-3,581 breast cancer surgeries. The center has 76 beds at its main campus (5 surgical and 2 chemotherapy beds), 20 beds at its Tianfu campus, and 15 beds at its Shangjin campus. It currently has 27 doctors, including 6 full professors, 6 associate professors, 7 postdoctoral fellows, and 6 PhDs. Guided by the innovative concept of "disease-centered care," the center has established a "center-based" specialty platform, integrating relevant breast subspecialties such as breast surgery, breast oncology, radiation oncology, pathology, radiology, ultrasound, rehabilitation, and nuclear medicine. This innovative approach creates a standardized, precise, and one-stop full-life-cycle management model for breast cancer patients, unique to West China Hospital.

Discipline Positioning and Benchmarking:

It is a key discipline of the Ministry of Education and a key specialty of the National Health and Family Planning Commission. Professor Chen Jie is currently the director of the Breast Disease Center. Her globally unique three-track sentinel lymph node biopsy can accurately predict the status of axillary lymph nodes, providing patients undergoing new or adjuvant chemotherapy with the opportunity to avoid axillary dissection and preserve upper limb function (reported at the 2021 ASCO meeting in the United States); her world-first single-incision oral endoscopic breast-conserving surgery provides breast cancer patients with a perfect scarless breast cancer surgery method (reported at the 2022 SABCS meeting in the United States and published in the top surgical journal, the British Journal of Surgery). In March 2025, Associate Professor Du Zhenggui, Deputy Director of the Center, was formally invited by the conference chairman to share West China Hospital's experience and achievements in endoscopic breast reconstruction and breast-conserving surgery with global experts at the Breast Cancer Conference in Barcelona (BBM). This marked the West China Hospital Breast Surgery Team's entry onto the international stage in endoscopic breast reconstruction and breast-conserving surgery.

The Department of Thyroid Surgery at West China Hospital of Sichuan University is one of the strongest centers in China in terms of clinical and academic strength in the field of thyroid surgery. It is a vice-chair unit of the Thyroid Surgery Committee of the Chinese Medical Association and the Thyroid Disease Committee of the Chinese Research Hospital Association, and is affiliated with the Thyroid (Parthyroid) Disease Diagnosis and Treatment Center (Institute) of West China Hospital of Sichuan University. The department has made globally leading technological contributions in parathyroid function preservation, achieved international breakthroughs in surgical treatment of advanced/complex thyroid cancer and P53 gene therapy for advanced thyroid cancer, and features a diversified approach to endoscopic thyroid surgery as its distinctive technical system. It is positioned as the source of standardized surgical standards for thyroid surgery in China and the "final destination" for the diagnosis and treatment of complex thyroid diseases.

Historical Origins and Spiritual Inheritance:

The Department of Thyroid Surgery at West China Hospital was founded by Professor Zhu Jingqiang and other senior experts. It has grown from a general surgery thyroid specialty group into a nationally recognized clinical and academic center for thyroid surgery. The department adheres to the treatment philosophy of "standardization, precision, minimally invasive procedures, and humanistic care," and has developed distinctive West China characteristics in areas such as parathyroid gland protection, recurrent laryngeal nerve monitoring, and comprehensive treatment of advanced thyroid cancer. Professor Zhu Jingqiang is currently the Director of the Department of Thyroid (Parathyroid) Disease Diagnosis and Treatment Center (Institute) at West China Hospital of Sichuan University. He previously served as the Director of Thyroid Surgery. He is the Vice Chairman of the Thyroid Surgery Physician Committee of the Chinese Medical Association and the Head of the Thyroid Surgery Group of the Surgical Committee of the Sichuan Medical Association. He has received honors such as the 6th China Physician Award and has been listed among the Top 100 Famous Doctors in China for three consecutive years.

Core business operational efficiency:

The department is renowned for its high level of expertise in the diagnosis and surgical treatment of complex and difficult thyroid and parathyroid diseases. Each year, it treats over 20% of patients referred from across the country for complex cases or repeat thyroid surgeries. The department boasts a high-caliber team of experts, including Professor Li Zhihui (Department Director), Professor Wei Tao (Party Branch Secretary and Deputy Director), Professor Lei Jianyong (Doctoral Supervisor, Deputy Director of General Surgery), Professor Su Anping, and Professor Gong Rixiang, representing three generations of academic professionals.

Discipline Positioning and Benchmarking:

The department is the vice-chair unit of the Thyroid Surgery Committee of the Chinese Medical Association, the vice-chair unit of the Thyroid Disease Committee of the Chinese Research Hospital Association, and the head unit of the Thyroid Surgery Group of the Surgical Committee of the Sichuan Medical Association. Professor Zhu Jingqiang, commissioned by the Thyroid Surgery Committee of the Surgical Branch of the Chinese Medical Association, authored and published the world's first "Expert Consensus on Parathyroid Gland Protection in Thyroid Surgery" in Chinese and English journals in 2015. The department is at an internationally advanced level in the treatment of advanced thyroid cancer with P53 and at an internationally leading level in the field of parathyroid function protection.

National-level Western China Echinococcosis (Hydatid Disease) Complex and Severe Case Diagnosis and Treatment Center; a benchmark for echinococcosis surgery on the Qinghai-Tibet Plateau; a platform for the diagnosis and treatment of brucellosis and other complex zoonotic infections in Southwest China.

1. Historical Origins and Spiritual Inheritance

The West China Center for Infectious Diseases originated from the Infectious Diseases Group of the Department of Medicine at West China Union University in 1914. The West China Center for Hepatic Echinococcosis subspecialty has grown and developed under the support of the Liver Surgery/Liver Transplantation Center. Since the 1980s, it has been handling echinococcosis cases referred from the Tibetan areas of the Qinghai-Tibet Plateau. After 2000, it gradually established a remote consultation system for echinococcosis in Tibetan areas. Since 2014, Wang Wentao's team has been working on the ex vivo liver resection and autologous liver transplantation (ERAT) for late-stage alveolar echinococcosis. The team has long been conducting hydatid disease outreach and surgery in echinococcosis endemic areas such as Ganzi and Aba, forming a disciplinary tradition of "emphasizing both technical breakthroughs and grassroots support". Inheriting the academic spirit of West China Hospital of High Morality and Professional Excellence, and taking root in the western and plateau regions to tackle infectious diseases and zoonotic diseases, we have established an "online + in-person" West China-Ganzi Echinococcosis Prevention and Control Model, undertaking the tasks of treating zoonotic diseases in the western region, providing grassroots assistance, and cultivating talents.

1. Core Business Operation Efficiency

The Echinococcosis MDT (Multidisciplinary Team) comprises hepatobiliary surgery, infectious diseases, radiology, ultrasound, pathology, pharmacology, and critical care medicine. It treats over 5,000 complex echinococcosis cases nationwide annually, performing approximately 200 complex hepatobiliary echinococcosis surgeries. The multidisciplinary outpatient clinic (MDT) for hepatobiliary echinococcosis is open every other Tuesday afternoon, with experts from hepatobiliary surgery, gastroenterology, infectious diseases, radiology, and ultrasound participating. The center has completed over 100 ERAT (Ex vivo autologous liver transplantation) cases, ranking first globally in single-center case volume, with a perioperative survival rate of 95% and a long-term survival rate of 93%. Brucellosis: Relying on the Infectious Diseases Center, we receive referrals of difficult brucellosis cases (including Brucella osteomyelitis and Brucella neuromyelitis) from western China every year, and conduct etiological, serological, and mNGS high-throughput gene sequencing to standardize long-term combined antibacterial regimens; we offer subspecialty outpatient services for zoonotic diseases and fever of unknown origin; we serve as the Sichuan Provincial Echinococcosis Clinical Research Center and the National Health Commission's Echinococcosis Medical Treatment Expert Group platform; and we provide remote coverage of the endemic areas in western Sichuan Plateau, conducting training for primary care physicians and mobile medical services.

1. Discipline Positioning

A national-level center for the diagnosis and treatment of complex and severe echinococcosis in western China; a benchmark for echinococcosis surgery on the Qinghai-Tibet Plateau; a platform for the diagnosis and treatment of brucellosis and other complex zoonotic infections in Southwest China. Focus: Echinococcosis (cystic/vesicular type) treated with medical medication, minimally invasive intervention, and complex surgical radical cure; precise pathogen diagnosis and long-term anti-infection management for brucellosis and its complications involving multiple systems including bone, nerves, and endocardium; construction of a complete MDT system encompassing prevention, medical medication, intervention, surgery, and postoperative follow-up; and leadership in developing standardized echinococcosis treatment protocols in Tibetan areas.

1. Core Advantages + National/Global Benchmarking

National benchmarks: The only large-scale and mature ERAT technology for echinococcosis in China, making it a leading echinococcosis surgery center in the country; its diagnostic capabilities for difficult subtypes of brucellosis (Neurobacterium and Spinal Brucella infection) rank among the top tier of infectious disease centers in China, on par with Huashan and Ditan Infectious Disease Centers; its echinococcosis MDT system and remote prevention and control model in Tibetan areas are national models; Weaknesses: Its understanding of the basic pathogenic mechanism of Brucella and the development of new vaccines are weaker than some specialized epidemiological research institutes in China.

Global benchmarks: ERAT ex vivo liver resection + autologous liver transplantation has the highest number of cases of end-stage alveolar echinococcosis in the world, and its technical solutions are internationally pioneering, comparable to echinococcosis surgery centers in Europe and Turkey; its multidisciplinary integrated management system for echinococcosis has been adopted internationally; shortcomings: insufficient independent translation of novel antiparasitic drugs and immunodiagnostic kits for echinococcosis.

Core Strengths: Interdisciplinary closed-loop MDT; radical surgery for complex alveolar echinococcosis in high-altitude areas; rapid mNGS identification of Brucella/echinococcosis pathogens; a two-way referral system between West China Hospital and Ganzi District for remote diagnosis and treatment and primary care; and the capability for radical surgical treatment of large, terminal alveolar echinococcosis lesions invading the hepatic hilum/inferior vena cava. For advanced alveolar echinococcosis (commonly known as "egg cancer"), the Wang Wentao team has performed nearly 120 ex vivo liver resection combined with autologous liver transplantation (ERAT), ranking first in the world in terms of surgical volume. The success rate is 100%, the perioperative survival rate is 95%, and the long-term survival rate is 93%, with safety and prognostic indicators reaching world-leading levels.

It is a national key discipline and national key clinical specialty of the Ministry of Education, and the affiliated unit of the Sichuan Provincial Thoracic Surgery Medical Quality Control Center. It has the qualifications of a standardized training base for thoracic surgery specialists. Relying on the Thoracic Tumor Research Institute (established in 2015, with Professor Liu Lunxu as the director), it has a research team of 7 PIs and 12 full-time technical personnel. It has established a Thoracic Tumor Research Institute (2000㎡), a lung cancer clinical database, and a tissue specimen bank, belonging to the national-level thoracic surgery research platform system. It has established a large-scale lung cancer clinical database (including more than 20,000 surgical cases) and a tissue specimen bank (stores more than 15,000 specimens). In the past decade, he has received more than 140 grants, including National Natural Science Foundation of China grants and provincial and ministerial-level research projects, with a total research funding of over 30 million yuan. He publishes an average of more than 90 SCI papers annually. He has won the first prize of Sichuan Provincial Science and Technology Progress Award and the first prize of Chinese Medical Science and Technology Award.

1. Historical Origins and Spiritual Inheritance

Founded in 1954 by Professor Yang Zhenhua, a pioneer of thoracic surgery in my country, the Department of Thoracic Surgery at West China Hospital is one of the earliest established cardiothoracic and thoracic surgery specialties in the country. Its core spirit is encapsulated in the motto "Innovation-led, Minimally Invasive First"—from pioneering extended resection of locally advanced lung cancer in the 1980s to leading the development of minimally invasive lung surgery in China for nearly 20 years, the department has consistently driven its progress through technological innovation. Inheriting the thoracic surgical spirit of "rigorousness, pragmatism, and overcoming difficulties," the department has gradually developed into a benchmark discipline in minimally invasive thoracic surgery, thoracic oncology surgery, lung transplantation, and enhanced recovery after surgery (ERAS) in China, starting with early open lung and esophageal surgeries.

2 Core Business Performance

The department is located in three campuses: the main campus, Shangjin Campus, and Tianfu Campus, with 227 beds. In 2023, it saw over 170,000 outpatient visits and performed over 7,000 surgeries annually. The department has 19 senior professionals, 7 doctoral supervisors, and 11 master's supervisors. Over 90% of the clinicians hold doctoral degrees.

1. Discipline positioning is aligned with the national standards.

It is a "National Key Discipline" of the Ministry of Education, a "National Key Clinical Specialty" of the National Health Commission, and the affiliated unit of the National Quality Control Center for Thoracic Surgery and the Sichuan Provincial Thoracic Surgery Medical Quality Control Center. For 13 consecutive years (2011-2023), it ranked fourth in the Fudan University National Hospital Specialty Reputation Ranking (first among comprehensive hospitals), ranking first in thoracic surgery among comprehensive hospitals nationwide, and second in the China Hospital Science and Technology Evaluation (STEM) ranking for thoracic surgery nationwide. Benchmarking internationally: its core members are members of the American Association of Thoracic Surgeons (AATS) and the European Society of Thoracic Surgeons (ESTS). Its technical system is cited by European and American peers, and it has led the development of multiple international and domestic thoracic surgery expert consensuses and clinical guidelines. It is one of the core training institutions for thoracoscopic surgery in Asia.

The department is affiliated with the Key Laboratory of Transplantation Engineering and Transplantation Immunology of the Ministry of Health (approved in 2002) and the Hepatobiliary and Pancreatic Diseases Research Laboratory. It undertakes dozens of projects funded by the National Natural Science Foundation of China, sub-projects of the 973 Program, and major projects funded by the Sichuan Provincial Department of Science and Technology. It has published over 100 SCI papers in internationally renowned journals such as *Gastroenterology* (IF=22.68), *Annals of Surgery* (IF=12.97), and *Nature Communications*. The department has received numerous awards, including the National Science and Technology Progress Award, the First Prize of Sichuan Provincial Science and Technology Progress Award (2022), and the First Prize of Hospital Science and Technology Innovation Award from the Chinese Hospital Association.

1. Historical Origins and Spiritual Inheritance

The Department of Hepatobiliary and Pancreatic Surgery at West China Hospital was established in 1980 by renowned Chinese hepatobiliary and pancreatic surgeons such as Ran Ruitu, Xiao Lujia, and Wu Heguang. The department boasts a glorious history: it was the first in the world to propose and successfully perform surgery on biliary ascariasis; it was the first in China to propose the classification and treatment principles for severe suppurative cholangitis; it was the first to establish animal models of suppurative cholangitis and intrahepatic bile duct stones; and it upholds the disciplinary spirit of overcoming difficulties, standardization, evidence-based practice, and minimally invasive innovation. It is one of the earliest centers in China to establish a specialized hepatobiliary and pancreatic surgery system. The core spirit is condensed into "daring to be the first and serving the country with technology"—from the world's first report of biliary ascariasis to the world's first eRPS procedure, technological innovation has always been driven by solving clinical problems.

1. Core Business Operation Efficiency

It comprises three subspecialties: liver, biliary tract, and pancreas. The number and quality of liver transplants are among the best in China (the team has completed nearly 3,000 liver transplants and tens of thousands of complex hepatobiliary surgeries). It has established a comprehensive diagnostic and treatment system for hepatobiliary and pancreatic tumors (MDT), integrated treatment of severe acute pancreatitis, complex biliary diseases, and hepatic echinococcosis. The volume of highly complex laparoscopic and robotic hepatobiliary and pancreatic surgeries is among the highest in China. The long-term survival rate after surgery for complex hepatobiliary and pancreatic malignancies reaches the top level in China. It is equipped with a biobank and a molecular pathology platform, enabling collaborative development of clinical diagnosis and translational medicine. The hospital has the highest number of laparoscopic gallbladder cancer re-operations among single centers internationally; it has completed the first domestic radical resection of hilar bile duct cancer with pancreatic head resection assisted by the da Vinci robot; and its total laparoscopic pancreaticoduodenectomy (LPD), one of the eight leading and distinctive medical technologies of West China Hospital, has a mortality rate of only about 1%, reaching the international advanced level.

1. Discipline Positioning and National/Global Benchmarking

A national key clinical specialty and a key clinical specialty of the National Health Commission; relying on the National Key Laboratory of Biological Therapy, the Key Laboratory of Transplantation Engineering and Transplant Immunology of the Ministry of Health, and the National Major Science and Technology Infrastructure for Translational Medicine, this department is a national-level research platform; a benchmark center for hepatobiliary and pancreatic surgery in China, with laparoscopic pancreaticoduodenectomy (LPD), minimally invasive radical resection of complex hilar cholangiocarcinoma, and ex vivo liver resection and autologous liver transplantation techniques reaching international advanced levels; the department is the leading unit in formulating guidelines for the diagnosis and treatment of severe pancreatitis and chronic pancreatitis. The department specializes in the surgical diagnosis and treatment and minimally invasive surgery of difficult hepatobiliary and pancreatic diseases, and is one of the advocates and promoters of precision liver resection in China. Benchmarking against top international hepatobiliary and pancreatic centers such as Johns Hopkins University and the University of Tokyo, it undertakes the tasks of referral and treatment of complex and critical hepatobiliary and pancreatic diseases, scientific research, and talent training in Southwest China.

It is a national key discipline and a national key clinical specialty of the Ministry of Education, affiliated with the West China Trauma Medicine Center's national-level trauma treatment research platform. It is complemented by the Orthopedics Research Institute and the State Key Laboratory of Stem Cell and Tissue Engineering, possessing research systems for bone tissue engineering and 3D-printed bone repair transformation. The West China Orthopedics Research Institute has formed a medical-engineering integration team with the University of Electronic Science and Technology of China and the State Key Laboratory of Polymer Materials of Sichuan University. Professor Wang Guanglin has presided over one National Key Research and Development Program and two National Natural Science Foundation of China projects, with a total funding exceeding 7 million RMB. In the past three years, the collaborative team has published over 30 high-level papers in top journals such as Advanced Functional Materials and Nano Energy (10 with an impact factor > 10). In the past five years, the Department of Orthopedics has received 12 national major special projects and 78 national-level research projects, with a total funding of over 100 million yuan.

1. Historical Origins and Spiritual Inheritance

Formerly known as the Hand Microsurgery Specialty Group founded by Professor Yang Zhiming in 1984, the Department of Traumatology was formally established in 1993, making it one of the earliest specialties in China to systematically develop trauma repair and functional reconstruction. The Department of Traumatology and Orthopedics at West China Hospital originated in the 1960s when Professor Rao Shucheng established a limb replantation research group, pioneering finger replantation, vascularized fibular grafting, and flap transplantation. The Hand Microsurgery Specialty Group was established in 1984, and the Department of Traumatology and Orthopedics was formally established in 1993, with Professor Yang Zhiming as its first head. This laid the foundation for the theoretical system of reconstructive surgery in China and founded the *Chinese Journal of Reconstructive Surgery*. The department upholds the West China Hospital Traumatology spirit of prioritizing trauma, repair and reconstruction, preserving function, and multidisciplinary collaborative treatment.

1. Core Business Efficiency

The department currently has 21 physicians, including 5 professors and 3 doctoral supervisors. It sees approximately 20,000 outpatients annually and performs nearly 4,000 surgeries per year. It undertakes emergency treatment of multiple injuries, severe limb trauma, and disaster-related injuries in Southwest China, possessing a complete closed-loop trauma management system encompassing pre-hospital care, emergency care, surgery, and rehabilitation. As a core department of the Sichuan Provincial and even Southwest China Trauma Emergency Center, it receives nearly a thousand patients annually from across the country with complex, revision, and complication-related conditions. In 2019, a Trauma Medicine Center was established, comprising six subspecialties: orthopedic trauma, neurotrauma, geriatric trauma, pediatric trauma, emergency trauma, and a trauma ICU.

1. Discipline positioning is aligned with the national standards.

The Department of Orthopedics at West China Hospital consistently ranks first in China in terms of reputation among Fudan University specialists and STEM scientific and technological achievements; its five-year total scientific and technological achievements (ASTEM) rank second in China. The Department of Traumatology is one of the birthplaces of reconstructive surgery in China, leading the Sichuan Provincial Trauma Treatment Alliance and establishing several national expert consensuses on multiple injuries, bone defects, and chronic osteomyelitis. Benchmarking globally: the team's core members maintain long-term academic exchanges with the BG Trauma Hospital in Germany and the AO Trauma Center in Switzerland, achieving internationally advanced standards in complex pelvic and hip injuries, limb microsurgical reconstruction, and tissue engineering repair of bone defects.

It is a standing committee member unit of the Orthopaedics Branch of the Chinese Medical Association, a vice chairman unit of the Spine Expert Working Committee of the Orthopaedics Branch of the Chinese Medical Doctor Association, a vice chairman unit of the Thoracolumbar Spine Committee of the Orthopaedics Branch of the Chinese Medical Doctor Association, an Asia-Pacific AO-Spine training base, a National Health Commission spinal endoscopy training center, and a western China scoliosis treatment center. It has undertaken more than 50 national and provincial-level research projects, published more than 100 SCI papers, and edited more than 20 monographs and nationally planned textbooks, including "Spinal Surgery." It has won five awards, including the National Science and Technology Progress Award, the Ministry of Education Science and Technology Progress Award, and the Provincial Science and Technology Progress Award.

1. Historical Origins and Spiritual Inheritance

The Department of Spinal Surgery at West China Hospital is affiliated with the Department of Orthopedics at West China Hospital (a National Key Discipline and a National Key Clinical Specialty of the Ministry of Education). Its origins can be traced back to the 1960s, when Professor Rao Shucheng began surgical treatment of spinal deformities and occipitocervical deformities. In the 1980s, it pioneered anterior spinal surgery in China, and its invention of the "vertebral nail" became a highly influential orthopedic internal fixation device at the time. Subsequently, it gradually developed into the Western China Scoliosis Treatment Center, the National Health Commission's Spinal Endoscopy Training Center, and the Asia-Pacific AO-Spine Training Base. Relying on the spinal cord research platform of the Orthopedic Research Institute, it has been incorporated into the national orthopedic research system, establishing research platforms for spinal biomechanics, 3D-printed spinal implants, and the transformation of spinal cord injuries. The core spirit is condensed into "pioneering the way and leading with minimally invasive techniques"—from anterior decompression of the thoracolumbar spine to spinal endoscopy, always breaking through surgical taboos with technological innovation.

1. Core Business Efficiency

Inheriting the spirit of precise orthodontics, minimally invasive decompression, preservation of nerve function, and multidisciplinary collaborative treatment, the Department of Spinal Surgery at West China Hospital is divided into four subspecialties: spinal deformities, cervical spine surgery, minimally invasive spinal surgery, and spinal bone diseases (spinal tumors, spinal tuberculosis). Currently, it has 7 senior professors, 8 associate professors, 5 doctoral supervisors, and 10 master's supervisors; it performs over 2,500 surgeries annually, ranking first in western China. It has developed four development directions—spinal deformities, cervical spine surgery, minimally invasive spinal surgery, and spinal bone diseases—and its diagnosis and treatment of spinal diseases are at a leading level in China. With a focus on highly complex surgeries such as severe rigid scoliosis, complex craniocervical junction lesions, spinal tumors, and spinal endoscopy, the hospital has established a comprehensive treatment system encompassing conservative treatment, minimally invasive endoscopy, open reconstruction, and en bloc resection of spinal tumors.

1. Discipline Positioning

Relying on the key disciplines of the Ministry of Education and the key clinical specialties of the National Health Commission, the Department of Orthopedics ranked 3rd in the country in STEM rankings in 2018 and 2021, and 2nd in the country in total scientific and technological achievements (ASTEM) over five years. Benchmarking against the national standards: it consistently ranks among the top tier of spinal surgery in China in the Fudan University Specialty Reputation Ranking and the China Hospital Scientific and Technological Achievement (STEM) rankings, and is a benchmark center for severe spinal deformities and cervical artificial disc replacement in China; it leads the Western Spinal Surgery Alliance and undertakes standardized training for spinal surgeons nationwide. Benchmarking globally: Long-term academic exchange with the Twin Cities Spine Center in the United States and the AO Spine Center in Germany; leading the world in the number of cervical artificial disc replacement surgeries; achievements in apical vertebral resection for severe rigid scoliosis and posterior decompression surgery for irreducible atlantoaxial dislocation have been cited in international spine surgery guidelines.

This institution is a national key discipline and a national key clinical specialty designated by the Ministry of Education. It was the lead unit, main implementing unit, and project leader for the 2013 National Health and Family Planning Commission's industry research project, "Safety and Efficacy Evaluation of New Clinical Technologies - Safety and Efficacy Evaluation of Joint Replacement." It is a major domestic base for accelerated rehabilitation in joint replacement surgery, having published 6 expert consensus statements and over 300 papers (over 150 SCI papers), 4 monographs, and 2 textbooks. It received one first prize in the Sichuan Provincial Science and Technology Progress Award. It has established a National Health Commission training base for orthopedic accelerated rehabilitation capacity building and a national demonstration ward for orthopedic blood management.

1. Historical Origins and Spiritual Inheritance

West China Hospital of Orthopedics began performing total joint replacement surgery in the 1970s, making it one of the earliest hospitals in China to perform this procedure. In 1998, Professor Pei Fuxing formally established the West China Joint Surgery Center, positioning it as a center for the diagnosis and treatment of complex joint diseases in western China. It is complemented by an orthopedic research institute and a digital orthopedic engineering center, serving as a training base for the National Health Commission's Enhanced Recovery After Surgery (ERAS) capacity building program for joint replacement, and is integrated into the national orthopedic research platform system. The center's core spirit is condensed as "Accelerated Recovery, Function First"—with "painless, bloodless, and thrombus-free" as the perioperative management goal, and Enhanced Recovery After Surgery (ERAS) as the core technical approach, promoting joint replacement from "surgical success" to "rapid and high-quality patient recovery."

1. Core Business Efficiency

Inheriting the spirit of precise reconstruction, minimally invasive hip preservation, accelerated recovery, and multidisciplinary collaboration, the Department of Joint Surgery at West China Hospital is divided into five subspecialties: hip joint surgery, knee joint surgery, joint revision surgery, femoral head necrosis with head preservation, and osteotomy and correction. Currently, it has 13 physicians, including 5 professors and 4 doctoral supervisors. Performing over 3,000 surgeries annually, it specializes in complex hip and knee joint replacements, prosthesis revisions, and joint infections, and is at the forefront domestically in femoral head necrosis with head preservation surgery and hip and knee periarticular osteotomy and correction surgeries. The average postoperative hospital stay for hip and knee replacement surgery is only 3.7 days, and the perioperative transfusion rate is 0.81%, reaching international advanced levels. The hospital achieved a perfect score of 100 in hip and knee replacement surgery for five consecutive years in the National Public Hospital Performance Evaluation. It has established a comprehensive treatment system covering joint preservation, primary replacement, prosthesis revision, and periprosthetic infection management, making its ERAS (Enhanced Recovery After Surgery) system a national benchmark.

1. Discipline Positioning

A key discipline of the Ministry of Education and a key clinical specialty of the National Health Commission, the unit where the Vice Chairman of the Orthopedics Branch of the Chinese Medical Association and the leader of the Joint Surgery Group is located, and the Western China Joint Surgery Center. Nationally, it is the birthplace and leading unit in the field of accelerated rehabilitation for joint replacement in China, leading the formulation of 6 expert consensuses on accelerated rehabilitation for joint replacement. Its reputation in Fudan University's specialty rankings and STEM science and technology evaluations consistently rank among the top tier of joint surgery in China, making it a national training base for joint surgery professionals. Globally, it has long-term academic collaborations with the Hamburg Joint Center in Germany and Johns Hopkins Orthopedics in the United States. Its research and development achievements in robotic joint replacement, 3D-printed customized prostheses, and biological prostheses have reached international advanced levels. Its perioperative blood management and rapid rehabilitation indicators are superior to the international average.

The Western Sports Injury Minimally Invasive Treatment Center is a vice-chairman unit of the Sports Medicine Branch of the Chinese Medical Association and the founding chairman unit of the Western China Sports Medicine Arthroscopy Alliance. It is the most influential comprehensive sports medicine center in western China, integrating medical treatment, teaching, and scientific research, and is a national key training center for master's, doctoral, and postdoctoral students.

1. Historical Origins and Spiritual Inheritance

Originating in the 1960s, with Professor Gong Jinyuan pioneering the diagnosis and treatment of sports injuries, and in the 1980s being the first in China to perform arthroscopic surgery, the center is one of the founding teams of arthroscopic surgery in my country. In 1996, Professor Li Jian established the Western China Arthroscopic Surgery Technical Training Center; in 2000, the Orthopedic Sports Medicine/Arthroscopic Subspecialty was formally established; and in 2013, the West China Sports Medicine Center was established. The center adheres to the treatment philosophy of "function first, precise minimally invasive surgery, early rehabilitation, and return to sports." Inheriting the spirit of "high moral character, professional excellence, pragmatism and innovation" of West China Medical Center, adhering to the concepts of minimally invasive reconstruction, functional priority, and integration of sports and medicine, we have built an integrated inheritance system for the diagnosis and treatment of sports injuries, arthroscopic technology training, and sports rehabilitation in western China; we have master's and doctoral programs and postdoctoral research stations.

1. Core Business Operation Efficiency

The hospital has nearly 60 beds; it sees nearly 20,000 outpatients and performs nearly 2,000 surgeries annually, ranking first in Sichuan Province and even western China. It has completed over 12,000 arthroscopic minimally invasive surgeries, with patients from all over China and countries and regions including the United States, Canada, Italy, Malaysia, and Singapore. The center boasts a surgical success rate exceeding 95.5%. It comprises four specialized medical teams focusing on knee, shoulder, elbow, wrist, foot, ankle, and hip joints, providing personalized treatment for each joint. Equipped with high-definition arthroscopy, surgical navigation, a KT2000 knee stability testing instrument, and a gait analyzer, the center undertakes national-level arthroscopic continuing education and training, as well as talent cultivation for the Western Sports Medicine Alliance. It provides medical care for professional athletes suffering sports injuries and ensures medical support for major sporting events. The center also accepts referrals of complex joint injuries from across the country and performs revision surgeries for sports injuries.

1. Discipline Positioning

The Western China Sports Injury Minimally Invasive Treatment Center is a vice-chairman unit of the Sports Medicine Branch of the Chinese Medical Association and the founding chairman unit of the Western China Sports Medicine Arthroscopy Alliance. Its focus is on: minimally invasive repair and reconstruction of complex limb joint sports injuries, articular cartilage/ligaments/menisci; postoperative functional rehabilitation; sports injury prevention; integration of sports medicine and sports health management; and handling revision joint surgeries referred from various parts of China.

1. Core Advantages + National/Global Benchmarking

- National Benchmark: Together with Huashan Hospital (ranked 2nd in the country) and Peking University Third Hospital (a national key clinical specialty), it forms the first echelon of sports medicine in China. The differentiated advantage of West China Hospital lies in the radiation of the western region and its comprehensive diagnosis and treatment capabilities for difficult joint swelling and pain diseases, with patients coming from the western region and even the whole country. Fudan University's reputation for specialized care and its STEM orthopedics subspecialty ranking among the top in the country; the West China Staging and Classification System for Multiple Ligament Injuries of the Knee Joint is an international original; the center was among the first in China to implement all-internal nonmetallic suture meniscus repair, large-scale allogeneic osteochondral transplantation, and tissue engineering repair of old Achilles tendon defects; it is one of the few centers in China that simultaneously covers minimally invasive reconstruction of the entire knee, shoulder, hip, ankle, elbow, and wrist joints, and serves as a western arthroscopic technology incubation platform. Compared with top hospitals in China (Peking University Third Hospital, Shanghai Sixth People's Hospital): it has differentiated advantages in the classification and reconstruction of complex knee dislocations and multiple ligament injuries; its overall strength in rotator cuff, hip labrum, and foot and ankle injuries is on par with the top in China. Weakness: The scale of the specialized sports rehabilitation system for competitive athletes is weaker than that of Taipei Third Hospital.

- Global benchmarking: The West China Classification System for Multiple Ligament Dislocations of the Knee Joint has been cited by international peers and can be compared with sports medicine centers in Europe and the United States (US HSS, Switzerland AO); the arthroscopic minimally invasive repair concept and platelet-rich plasma (PRP) tendon and cartilage repair program are in line with international mainstream practices; Shortcomings: The scale of clinical translation of cartilage regeneration and tissue-engineered tendons still lags behind top international centers.

- Core Advantages: Integrated reconstruction of complex joints with multiple ligament injuries, revision surgery after arthroscopy, full coverage of subspecialties of all joints, and the "3+5 new model of sports medicine and health management" that integrates sports and medicine.